Skip to main content
Kreisklinik EbersbergKreisklinik Ebersberg
MenüSchliessen
Umfassender Blick auf Mensch und Erkrankung

Akutgeriatrie mit Parkinsonschwerpunkt

Chefarzt der Akutgeriatrie mit Parkinsonschwerpunkt

Prof. Dr. J. Schwarz
Prof. Dr. med. Johannes Schwarz
Chefarzt der Akutgeriatrie & Parkinson
Zur Vita
Vita schliessen

1980Abitur, Wüllenweber Gymnasium, Bergneustadt
1981 - 1982Violoncello-Studium, Hochschule für Musik und darstellende Kunst, Wien
1982 - 1989Studium der Humanmedizin in Regensburg, Würzburg, Louisville und Boston
  

1989 - 1996Arzt in Weiterbildung, Neurologische Klinik, LMU Großhadern
1996 - 1998Oberarzt, Neurologische Klinik, Universität Ulm
1998 - 2001Visiting Associate Professor in Biology, California Institute of Neurology
2001 - 2011Professor und stv. Direktor, Neurologische Klinik, Universitätsklinik Leipzig und Visiting Associate, California Institute of Technology
2008 - 2011Gastprofessor, Pochon Cha Universität, Seoul, Südkorea
2009 - 2010Gastprofessor Université 3, Montpellier
2011 - 2023Chefarzt, Geriatrie und Parkinson-Schwerpunkt, Klinik Haag
seit 2023Chefarzt Abteilung Akutgeriatrie mit Parkinson-Schwerpunkt, Kreisklinik Ebersberg

1990Approbation
1996Facharzt Neurologie
1996Zusatzqualifikation Neurophysiologie
1997Zusatzqualifikation neurologische Intensivmedizin
1998Habilitation
2011Berufung als ordentlicher Professor

2000Richard-Heikkila-Preis der National Parkinson Foundation
2003Posterpreis der Deutschen Parkinson Gesellschaft 2003

Originalarbeiten

  1. Moessner J, Schwarz J, Fischbach W. Influence of "calcium2+-channel-blockers on exocrine pancreatic secretion by isolated rat acini. Res Exp Med Berl 1988; 188:255-265

  2. Gupta M, Schwarz J, Chen XL, Roisen FJ. Gangliosides prevent MPTP toxicity in mice - an immunocytochemical study. Brain Res 1990; 527:330-334

  3. Tatsch K, Schwarz J, Oertel WH, Kirsch CM. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 1991; 12: 699-707 

  4. Schwarz J, Trenkwalder C, Arnold G, Gasser T, Oertel WH. Folinic Acid Therapy Fails to Improve Early Parkinson's Disease: A Two Week Placebo Controlled Clinical Trial. J Neural Transm (PD section); 1992, 4: 35-41

  5. Schwarz J, Tatsch K, Vogl T, Arnold G, Trenkwalder C, Kirsch CM, Oertel WH. Marked reduction of striatal dopamine D2 receptors as detected by 123I-IBZM-SPECT in a Wilson's disease patient with generalized dystonia. Mov Disord 1992; 7:58-61

  6. Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, Oertel WH. 123I-Iodobenzamide-Spect predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992; 42:556-561

  7. Tatsch K, Schwarz J, Oertel WH, Kirsch CM. Idiopathic Parkinson Syndrome: I-123 IBZM SPECT findings in drug naive and treated patients. Eur J Nucl Med 1992; 19:556-561

  8. Oertel WH, Tatsch K, Schwarz J, Trenkwalder C, Scherer J, Weinzierl M, Kirsch CM. Reduction of striatal dopamine D2 receptors in 123I-IBZM-SPECT relates to neurological deficit in treated Wilson's disease. Ann Neurol 1992; 32: 743-748

  9. Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson syndromes. Arch Neurol 1992; 49:1131-1134 

  10. Schwarz J, Tatsch K, Arnold G, Ott M, Trenkwalder C, Kirsch CM, Oertel WH. 123I-Iodo-benzamide-Spect in 83 patients with de novo parkinsonism. Neurology 1993; 43 Suppl. 6: 17-20 

  11. Tatsch K, Schwarz J, Kirsch CM. ZNS-SPECT: Rezeptorszintigraphie mit 123J-IBZM und 123J-Iomazenil. Der Nuklearmediziner 1993; 16:143-150

  12. Baumert T, Kleber G, Schwarz J, Stabler A, Lamerz R, Mann K. Reversible hyperkinmesia in a patient with autoimmune polyglandular syndrome type-I. Clinical Investigator 2003; 71:924-927

  13. Arnold G, Bondy B, Bandmann O, Gasser T, Schwarz J, Trenkwalder C, Wagner M, Poewe W, Oertel WH. 3H-spiperone binding to lymphocytes fails in the differential diagnosis of de novo Parkinson syndromes. J Neural Transm {P-D Sect} 1993; 5:107-116 

  14. Oertel WH, Schwarz J, Tatsch K, Arnold G, Gasser T, Kirsch CM. IBZM-SPECT as predictor for dopaminergic responsiveness of patients with de novo Parkinsonian syndrome. Advances of Neurology 1993; 60:519-524

  15. Schwarz J, Antonini A, Kraft E, Tatsch K, Vogl T, Kirsch CM, Leenders KL, Oertel WH. Treatment with D-penicillamine improves dopamine D2 receptor binding and T2-signal intensity in de novo Wilson's disease. Neurology 1994; 44:1079-1082

  16. Arnold G, Trenkwalder C, Schwarz J, Oertel WH. Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug induced psychosis. Mov Disord 1994; 9:238-239

  17. Arnold G, Tatsch K, Oertel WH, Vogl Th, Schwarz J, Kraft E, Kirsch CM. Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI. J Neural Trans 1994; 42 Suppl.:111-118

  18. Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL. 11C-raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-DOPA and lisuride therapy on striatal dopamine D2 receptors. Neurology 1994; 44:1325-1329

  19. Schwarz J, Antonini A, Tatsch K, Kirsch CM, Oertel WH, Leenders KL. Comparison of 123I-IBZM-SPECT and 11C-raclopride-PET findings in patients with parkinsonism. Nucl Med Comm 1994; 15:806-813

  20. Scherer J, Tatsch K, Schwarz J, Oertel WH, Kirsch CM, Albus M. Striatal D2 dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biol Psych 1994; 36:627-629

  21. Scherer J, Tatsch K, Schwarz J, Oertel WH, Konjarczyk M, Albus M. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Scand 1994; 90:266-268

  22. Vogl Th J, Steiner S, Hammerstingl R, Schwarz J, Kraft E, Weinzierl M, Felix R. MRT der Leber bei Morbus Wilson. Fortschr Röntgenstr 1994; 160:40-45

  23. Trenkwalder C, Stiasny K, Pollmächer T, Wetter T, Schwarz J, Kohnen R, Katzenwadl J, Krüger HP, Ramm S, Künzel M, Oertel WH. L-DOPA therapy of uremic and idiopathic restless legs syndrome: a double blind, crossover trial. Sleep 1995, 18:681-688

  24. Trenkwalder C, Schwarz J, Gebhard J, Ruland D, Trenkwalder P, Hense HW, Oertel WH. Starnberg trial on epidemiology of parkinsonism and hypertension in the elderly: prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 1995; 52:1017-1022

  25. Schwarz TF, Pfister HW, Schwarz J, Pauli C, Jäger G. Meningitis nach Aufenthalt im Mittelmeerraum, durch Sandfliegenvirus verursacht. Nervenarzt 1995; 66:789-791

  26. Oertel WH, Trenkwalder C, Gasser T, Schwarz J, Bucher SF, Eichhorn T, Pogarell O, Künig G, Arnold G, Bandmann O, Dodel RC. Epidemiological, genetic, pharmacological, kinesiological, nuclear medical (IBZM-SPECT), standard and functional MRI studies on Parkinson's disease and related disorders and economic evaluation of Parkinson's disease therapy - clinical projects in the BMFT-research program Munich: "Parkinson's disease and other basal ganglia disorders". J Neural Transm (PD section) 1995; 46 Suppl:325-337

  27. Gerlach M, Götz M, Dirr A, Kupsch A, Janetzky B, Oertel W, Sautter J, Schwarz J, Reichmann H, Riederer P. Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin. Neurochem Int 1996; 28:41-49 

  28. Schwarz J, Weis S, Kraft E, Tatsch K, Bandmann O, Mehrain P, Vogl T, Oertel WH. Signal changes on MRI and increase of reactive micro-, astrogliosis and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 1996; 60:98-101 

  29. Schwarz J, Oertel, WH, Tatsch K. Iodine-123-iodobenzamide binding in parkinsonism: Reduction by dopamine agonists but not L-Dopa. J Nucl Med; 1996; 37:1112-1115

  30. Eichhorn T, Gasser T, Mai N, Marquardt C, Arnold G, Schwarz J, Oertel WH. Computational analysis of automated handwriting movements: a rapid method to detect dopamimetic effects in Parkinson's disease. Mov Disord 1996; 11:289-297 

  31. Kupsch A, Sautter J, Schwarz J, Gerlach M, Riederer P, Oertel WH. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 1996; 741:185-196

  32. Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Long term changes of dopamine D2 receptors in patients with Parkinson's disease: a study with PET and [11C]raclopride. Mov Disord 1997; 12:33-38

  33. Scheidtmann K, Schwarz J, Holinski-Feder E, Gasser Th, Trenkwalder C. Paroxysmal choreoathetosis - a disorder related to Huntington's disease. J Neurol 1997; 244:395-398

  34. Schwarz J, Scheidtmann K, Trenkwalder C. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa. Eur Neurol 1997; 37:236-238

  35. Schwarz J, Planck J, Briegel J, Straube A. Single-fiber electromyography, nerve conduction studies and conventional electromyography in patients with critical-illness polyneuropathy: evidence for a lesion of terminal motor axons. Muscle Nerve 1997; 20:696-701

  36. Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, Fieber RS, Hahn K, Kung HF. Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997; 24:415-421

  37. Scherer J, Tatsch K, Albus M, Schwarz J, Mager T, Oertel WH. Dopamine D2 receptor occupancy during treatment with haloperidol decanoate. Eur Arch Psychiatry Clin Neurosci 1997; 247:104-106 

  38. Welz A, Pogarell O, Tatsch K, Schwarz J, Cryssagis K, Reichart B. Surgery of the thoracic aorta using deep hypothermic total circulatory arrest. Are there neurological consequences other than frank cerebral defects. Eur J Cardiothorac Surg 1997; 11:650-656

  39. Plaschke M, Schwarz J, Dahlheim H, Backmund H, Trenwalder C. Cardiovascular and renin responses to head-up tilt test in parkinsonism. Acta Neurol Scan 1997;.96: 206-210

  40. Schwarz J, Kornhuber M, Bischoff C, Straube A. Electromyography of the external anal sphincter in patients with Parkinson' disease and multiple system atrophy. Muscle Nerve 1997; 20:1167-1172

  41. Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH. 123I-IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Mov Disord 1997; 12:898-902

  42. Kupsch A, Pogarell O, Schwarz J, Straube A, Oertel WH Tatsch K, Linke R. Parkinson’s disease and tumor in the SMA, a re-evaluation. J Neurol Neurosurg Psychiatry 1997; 63:811-812 

  43. Arnold G, Schwarz J, Macher C, Oertel WH. Domperidone is superior to ondansetron in acute apomorphine challenge in previously untreated parkinsonian patients - a double blind study. Parkinsonism & Related Disorders 1997; 3:191-193 

  44. Schwarz J, Tatsch K, Gasser T, Arnold G, Pogarell O, Künig G, Oertel WH. 123I-IBZM binding compared to long term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998; 13:16-19 

  45. Schwarz SC, Schwarz J, Sautter J, Oertel WH, Effects of macrophage migration inhibitory factor and macrophage migration stimulatory factor on function and survival of foetal dopaminergic grafts in the 6-hydroxydopamine model of Parkinson´s disease. Exp Brain Res 1998; 120: 95 -103 
  46. Götz ME, Breithaupt W, Sautter J, Kupsch A, Schwarz J, Oertel WH, Youdim MBH, Riederer P, Gerlach M. Chronic TVP-1012 (rasagiline) dose - activity response of monoamine oxidases A and B in the brain of the common marmoset. J Neural Transm 1998; 52 Suppl.:271-278

  47. Borasio GD, Linke R, Schwarz J, Schlamp V, Abel A, Mozley PD, Tatsch K. Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT-SPECT. J Neurol Neurosurg Psychiatry 1998; 65:263-265

  48. Schwarz J, Scherer J, Trenkwalder C, Mozley PD, Tatsch K. Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy? Psychiatry Res: Neuroimaging 1998; 83:23-28 

  49. Schwarz SC, Seufferlein T, Liptay S, Schmid RM, Kasischke K, Foster OJF, Daniel S, Schwarz J. Microglial activation in multiple system atrophy: a potential role for NF-kappaB/Rel Proteins. Neuroreport 1998; 9:3029-3032

  50. Kraft E, Schwarz J, Gasser T, Arnold G, Pfluger T, Oertel WH. The combination of hypointense and hyperintense signal changes in the basal ganglia is specific for multiple system atrophy. Arch Neurol 1999; 56: 125-128

  51. Schwarz J, Kraft E, Vogl T, Arnold G, Tatsch K, Oertel WH. Relative quantification of signal on T2-weighted MRI images in the basal ganglia: Limited value in differential diagnosis of patients with parkinsonism. Neuroradiol; 1999; 41: 124-127 

  52. Storch A, Ludolph AC, Schwarz J. HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpyridine (MPP+) via impairment of energy metabolism. Neurochem Int 1999; 35:393-403 

  53. Sperfeld AD, Collatz MB, Baier H, Palmbach M, Storch A, Schwarz J, Tatsch K, Reske SN, Joosse M, Heutink P, Ludolph AC. FTDP-17: An early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol 1999; 46:708-715  

  54. Storch A, Kaftan A, Burkhardt K, Schwarz J. 1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism. Brain Res 2000; 855:67-75

  55. Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T, Tatsch K. Striatal dopamine transporter binding assessed by [I-123] IPT and single photon emission tomography in patients with early Parkinson’s disease: Implications for a preclinical diagnosis. Arch Neurol 2000; 57:205-208

  56. Storch A, Blessing H, Bareis M, Jankowski S, Schwarz J. Catechol-O-methyl transferase (COMT) inhibition enantio-selectively attenuates levodopa toxicity in primary dopaminergic neurons in vitro. Mol Pharmacol 2000; 57:589-594

  57. Storch A, Kaftan A, Burkhardt K, Schwarz J. Cytotoxicity of 6-hydroxydopamine towards human SH-SY5Y dopaminergic neuroblastoma cells is independent from energy metabolism. J Neural Transm PD Section 2000; 107: 281-293 

  58. Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic REM sleep behavior disorder: comparison to Parkinson’s disease and controls. Brain; 2000; 123:1155-1160

  59. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MH, Sips HJ, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000; 15:503-510 

  60. Storch A, Burkhardt K, Ludolph AC, Schwarz J. Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J Neurochem. 2000 75:2259-2269 

  61. Labarca, C., Schwarz J, Deshpande, P., Schwarz, S., Nowak, M.W., Fonck, C., Nashmi, R., Kofuji, P., Dang, H., Shi, W., Fidan, M., Khakh, B.S., Chen, Z., Bowers, B.J., Boulter, J., Wehner, J.M., and Lester, H.A. Point mutant mice with hypersensitive 4 nicotinic receptors show dopaminergic deficits and increased anxiety.  PNAS 2001, 98:2786-2791

  62. Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. Nucl Med Commun 2001; 22:721-725 

  63. Storch A, Paul G, Csete M, Boehm BO, Carvey PM, Kupsch A, Schwarz J. Long-term proliferation and dopaminergic differentiation of human mesencephalon-derived neural precursor cells. Exp Neurol 2001; 170:317-325

  64. Kraft E, Schwarz J, Trenkwalder C, Oertel WH. Hyperintense lateral rim and hypointense putamen are typical but not exclusive of multiple system atrophy - In reply. Arch Neurol 2001; 58:1026

  65. Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MBH, Riederer P, Gerlach M, Oertel WH. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegeline. J Neural Transm 2001; 108:985-1009

  66. Storch A, Ott S, Hwang YI, Ortmann R, Hein A, Frenzel S, Matsubara K, Collins M, Ohta S, Wolf HU, Schwarz J. Selective dopaminergic toxicity of isoquinoline derivatives related to Parkinson’s disease: studies using heterologous expression systems of the dopamine transporter. Biochem Pharmacol 2002; 63:909-920

  67. Arnold G, Tatsch K, Kraft E, Bandmann O, Wächter T, Oertel WH, Schwarz J. Steele-Richardson-Olszewski syndrome: relation of dopamine D2 receptor binding and subcortical lesions in MRI. J Neural Transm 2002; 109:503-512

  68. Storch A, Schwarz J. Neural stem cells and neurodegeneration. Curr Opin Invest Drugs 2002, 3:774-781

  69. Arnold G, Tatsch K, Kraft E, Bandmann O, Wächter T, Oertel WH, Schwarz J. Steele-Richardson-Olszewski syndrome: Reduction of dopamine D2 receptor binding relates to the severity of midbrain atrophy in vivo - an IBZM-SPECT and MRI study. Mov Disord 2002; 17:557-562

  70. Lehmensiek V, Tan EM, Schwarz J, Storch A. Expression of mutant alpha-synuclein enhances dopamine transporter mediated MPP+ toxicity in HEK 293 cells. NeuroReport 2002;13:1279-83

  71. Blessing H, Bareiss M, Zettlmeisl H, Schwarz J, Storch A. Catechol-O-methyltransferase inhibition protects against 3,4-dihydroxyphenylalanine (DOPA) toxicity in primary mesencephalic cultures: new insights into levodopa toxicity. Neurochem Int 2003; 42:139-151

  72. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Hauser RA, Poewe WH, Brooks DJ, REAL-PET Study group. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54:93-101 

  73. Fonck C, Nashmi R, Deshpande P, Marks MJ, Riedel A, Schwarz J, Collins AC, Labarca C, Lester HA. Increased sensitivity to agonist-induced seizures and Straub tal in knock-in mice carrying hypersensitive a4 nicotinic receptors. J Neurosci 2003; 23:2582-2590

  74. Eisensehr I, Linke R, Tatsch K. Kharraz B, Gildehaus JF, Wetter CT, Trenkwalder C, Schwarz J, Noachter S. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep 2003; 26:507-12

  75. Gerhard A, Banati R, Goerres GB, Cagnin A, Myers R, Gunn RN, Turkheimer F, Good CD, Mathias CJ, Quinn N, Schwarz J, Brooks DJ. [11C](R)PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 2003; 61:686-9 

  76. Rahman Z, Schwarz J, Wein M, Gold SJ, Kovoor A, Chen CK, Self D, Neve RL, Schwarz SC, Lester HA, Simon MI, Nestler EJ. RGS9 modulates dopamine signaling in the basal ganglia. Neuron. 2003; 38:941-52 (Rahman and Schwarz contributed equally) 

  77. Storch A, Lester HA, Boehm BO, Schwarz J. Functional characterization of dopaminergic neurons derived from murine mesencephalic stem cells. J Chem Neuroanat 2003; 26:133-42

  78. Milosevic J, Storch A, Schwarz J. Spontaneous apoptosis in murine free floating neurospheres. Exp Cell Res 2004; 294:9-17 

  79. Storch A, Hwang YI, Gearhart DA, Beach JW, Neafsey EJ, Collins MA, Schwarz J. Dopamine transporter-mediated cytotoxicity of ß-carbolinium derivatives related to Parkinson’s disease: relationship to transporter-dependent uptake. J Neurochem 2004; 89:685-694

  80. Pöpperl G, Ruzicka E, Storch A, Gasser T, Tatsch K, Schwarz J. Comparison of α-dihydroergocryptine and levodopa monotherapy in Parkinson’s disease: assessment of disease progression with [123I]IPT SPECT. J Neural Transm 2004; 111:1041-1052

  81. Günther P, Storch A, Schwarz J, Sabri O, Steinbach P, Wagner A, Hesse S. Basal ganglia involvement of a patient with SCA 17 – a new form of autosomal dominant spinocerebellar ataxia. J Neurol 2004; 251:896-897

  82. Orb S, Wieacker J, Labarca C, Fonck C, Lester HA, Schwarz J. Knockin mice with Leu9'Ser alpha4-nicotinic receptors: substantia nigra dopaminergic neurons are hypersensitive to agonist and lost postnatally. Physiol Genomics 2004; 18:299-307 

  83. Hermann A, Gastl R, Fiedler J, Liebau S, Popa MO, Boehm BO, Lerche H, Schwarz J, Brenner R, Storch A. Efficient generation of neural stem cells from adult human bone marrow stromal cells. J Cell Sci 2004; 117:4411-4422

  84. Storch A, Sabolek M, Milosevic J, Schwarz SC, Schwarz J. Midbrain-derived neural stem cells: from basic science to therapeutic options. J Cell Tiss Res 2004; 318:15-22 

  85. Schwarz J, Storch A, Pogarell O, Tatsch K. Striatal dopamine transporter binding in Parkinson’s disease: follow up for 7.5 years. J Nucl Med 2004; 45:1694-1697

  86. Storch A, Ludolph AC, Schwarz J. Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J Neural Transm 2004; 111:1267-1286

  87. Tapper A, McKinney SS, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA. Nicotine activation of α4 receptors is sufficient for reward, tolerance and sensitization. Science 2004; 306:1029-1032

  88. Hesse S, Barthel H, Schwarz J, Sabri O, Müller U. Advances in in-vivo imaging of serotonergic neurons in neurological diseases with affective disorders. Neuroscience and Biobehavioral Reviews 2004; 28:547-563

  89. Gerhard A, Schwarz J, Myers R, Wise R, Banati R. Evolution of microglial activation in patients after ischemic stroke: A [11C] (R)-PK11195 PET study. NeuroImage 2005; 15:282-290

  90. Storch A, Kornhass M, Schwarz J. Acanthocytosis: reference values for dry, wet and diluted smears. J Neurol 2005; 252:84-90

  91. Kovoor A, Seyffarth P, Ebert J, Barghshoon S, Chen CK, Schwarz SC, Axelrod JD, Simon MI, Lester HA, Schwarz J. D2 dopamine receptors colocalize RGS9 2 via the RGS9 DEP domain and RGS9 knockout mice develop dyskinesias associated with dopamine pathways. J Neurosci 2005; 25:2157-2165

  92. Milosevic J, Schwarz SC, Krohn K, Poppe M, Storch A, Schwarz J. Low atmospheric oxygen avoids maturation, senescence and cell death of murine mesencephalic neural precursors. J Neurochem 2005; 92:718-729

  93. Milosevic J, Storch A, Schwarz J. Cryopreservation does not affect proliferation and multipotency of murine neural precursor cells. StemCells 2005; 23:681-688 

  94. Winkler D, Tittgemeyer M, Schwarz J, Strecker K, Gielen F, Strauss G, Lindner D, Meixensberger J. Evaluation of brain shift during neurosurgical biopsies guided by interventional magnetic resonance imaging. J Neurol Neurosurg Psychiatr 2005; 76:1161-3

  95. Arnold G, Gasser T, Storch A, Lipp A, Kupsch A, Hundemer HP, Schwarz J. High doses of pergolide are efficacious and safe in progressed Parkinson’s disease. Arch Gerontol Geriatrics 2005; 41:239-251

  96. Storch A, Trenkwalder C, Oehlwein C, Winkelmann J, Polzer U, Hundemer HP, Schwarz J. High-dose treatment with pergolide in Parkinson’s disease patients with motor fluctuations and dyskinesias. Parkinsonism & Rel Disord 2005; 11:393-398 

  97. Oertel WH, Wolters EC, Sampiao C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset DG, Arnold G, Leenders KL, Hundemer HP, Lledo A, Wood A, Frewer P, Schwarz J. Pergolide versus L-Dopa monotherapy in early Parkinson’s disease patients: the Pelmopet* study. Mov Disord 2006; 21:343-353 

  98. Lehmensiek V, Tan EM, Liebau S, Lenk T, Zettlmeisl H, Schwarz J, Storch A. Dopamine tranporter mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant α-synucleins related to Parkinson’s disease. Neurochem Int 2006; 48:329-340 

  99. Schneider JP, Reinohs M, Prothmann S, Puccini S, Dalitz B, Schwarz J, Zimmer C, Then Bergh F. Subcortical right parietal AVM: rotational vertigo and caloric stimulation fMRI support a parietal representation of vestibular input. J Neurol 2006; 253:253-5

  100. Schwarz J, Schwarz SC, Dorigo O, Stuetzer A, Wegner F, Labarca C, Deshpande P, Gil JS, Berk AJ, Lester HA. Enhanced expression of hypersensitive α4 nAChR in adult mice increases the loss of midbrain dopaminergic neurons. FASEB J, 2006; 20:935-46 

  101. Hermann A, Maisel M, Liebau S, Kim DW, Wegner F, Gerlach M, Schwarz J, Kim KS, Storch A. Multipotent neural stem cells from the adult tegmentum differentiate into functional dopamineregic neurons. StemCells 2006; 24:949-64 

  102. Milosevic J, Juch F, Storch A, Schwarz J. Low extracellular calcium is sufficient for survival and proliferation of murine mesencephalic neural precursor cells. Cell Tiss Res 2006; 324:377-84 

  103. Storch A, Heimhilger E, Schwarz J. Increased periodontal pathology in Parkinson’s disease. J Neurol 2006; 253:608-611

  104. Schwarz SC, Wittlinger J, Schober R, Storch A, Schwarz J. Transplantation of human neural precursor cells in the 6-OHDA lesioned rats: effect of immunosuppression with Cyclosporine A. Parkinsonism & Rel Disord 2006; 12:302-308

  105. Hermann A, Liebau S, Gastl R, Fickert S, Habisch HJ, Fiedler J, Schwarz J, Brenner R, Storch A. Comparative analysis of neuroectodermal differentiation capacity of human bone marrow stromal cells using various conversion protocols. J Neurosci Res 2006; 83:1502-151

  106. Seeman P, Schwarz J, Chen JF, Szechtman H, Perrault M, McKnight GS, Roder JC, Quirion R, Boksa P, Srivastava LK, Yanai K, Weinshenker D, Sumiyoshi T. Psychosis pathways converge via D2High dopamine receptors. Synapse 2006; 60:319-346 

  107. Hermann A, Maisel M, Liebau S, Gerlach M, Kleger A, Schwarz J, Kim KS, Antoniadis G, Lerche H, Storch A. Mesodermal cell types induce neurogenesis from adult human hippocampal progenitor cells. J Neurochem 2006; 98:629-40

  108. Then Bergh F, Niklas A, Strauss A, von Ahsen N, Niederwieser D, Schwarz J, Wagner A, Haifa AA. Rapid progression of myelodysplastic syndrome to acute myeloid leukemia on sequential azathioprine, IFN beta and copolymer-1 treatment in a patient with multiple sclerosis. Acta Haematol 2006; 116:207-10

  109. Sabolek M, Herborg A, Schwarz J, Storch A. Dexamethasone blocks astroglial but not neuronal differentiation from rat mesencephalic neural precursors. NeuroReport 2006; 17:1719-1723

  110. Strecker K, Schneider JP, Barthel H, Hermann W, Wegner F, Schwarz J, Sabri O, Zimmer C. Profound Midbrain Atrophy in Patients with Wilson’s Disease and Neurological Symptoms? J Neurol 2006; 253:1024-1029

  111. Hesse S, Oehlwein C, Barthel H, Schwarz J, Polster D, Wagner A, Sabri O. Possible impact of dopamine SPECT on decision-making for drug treatment in parkinsonian syndrome. J Neur Transm 2006;  113:1177-1190

  112. Milosevic J, Brandt A, Roemuss U, Arnold A, Wegner F, Schwarz SC, Storch A, Zimmermann H, Schwarz J. Uracil nucleotides stimulate human neural precursor cell proliferation and dopaminergic differentiation: Involvement of MEK-ERK signalling. J Neurochem 2006; 99:913–923

  113. Storch A, Hwang YI, Bringmann G, Ott S, Brueckner R, Schwarz J. Cytotoxicity of chloral derived b–carbolines in neuroblastoma cells and heterologous expression systems of the dopamine transporter. J Neural Transm 2006; 113:1895-1901 

  114. Milosevic J, Maisel M, Wegner F, Leuchtenberger J, Wenger RH, Gerlach M, Storch A, Schwarz J. Lack of HIF-1α impaires midbrain neural precursor cells involving VEGF signalling. J Neurosci 2007; 27:412-421

  115. Strecker K, Schneider JP, Sabri O, Wegner F, Then Bergh F, Schwarz J, Hesse S. Responsiveness to a dopamine agonist in Holmes tremor – Case report. Eur J Neurol 2007; 14:e9-e10

  116. Winkler D, Strauss G, Helm J, Goldammer A, Schneider JP, Schwarz J, Meixensberger J. MicroTargeting® platform: an individual stereotaxic device in functional neurosurgery. Int J CARS 2007; 1:295-299

  117. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, Padovani A, Giubbini R, Bonuccelli U, Volterrani D, Holmes C, Kemp P, Tabet N, Meyer I, Reininger C; DLB Study group. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007; 4:305-313

  118. Maisel M, Herr A, Milosevic J, Hermann A, Habisch HJ, Schwarz SC, Kirsch M, Antoniadis G, Brenner R, Hallmeyer-Elgner S, Lerche H, Schwarz J, Storch A. Transcription profiling of adult and fetal human neuroprogenitors identifies divergent paths to maintain the neuroprogenitor cell state. Stem Cells 2007; 5:1231-40

  119. Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, Oertel WH, Tolosa E, Lees AJ, Poewe W. Role of DAT-SPECT in the diagnostic work-up of parkinsonism. Mov Disord 2007, 22:1229-38 

  120. Milosevic J, Schwarz SC, Poppe M, Dieterlen M, Maisel M, Storch A, Schwarz J. Dopamine D3 receptor stimulation fails to promote dopaminergic neurogenesis of murine and human midbrain derived neural precursor cells in vitro. Stem Cells Dev 2007. 16:625-635

  121. Strecker K, Schneider JP, Wegner F, Hesse S, Schwarz J. Eye of the Tiger sign in Multiple System Atrophy - Case Report. Eur J Neurol 2007; 11:e1-2 

  122. Wegner F, Strecker K, Schwarz J, Wagner A, Heinritz W, Sommerer F, Thal DR, Schneider JP, Kendziorra K, Sabri O. Vascular parkinsonism and dementia in a CADASIL case with intact nigrostriatal dopaminergic system. J Neurol 2007; 254:1743-1745

  123. Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T; ADVANS Study Group. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol 2008; 65:577-583

  124. Sabolek M, Mieskes I, Lenk T, Lehmensiek V, Schwarz J, Storch A. Stage-dependent vulnerability of fetal mesencephalic neuroprogenitors towards dopaminergic neurotoxins. Neurotoxicology 2008; 4:714-721 

  125. Hesse S, Strecker K, Winkler D, Luthardt J, Scherfler C, Reupert A, Oehlwein C, Barthel H, Schneider JP, Wegner F, Meyer P, Meixensberger J, Sabri O, Schwarz J. Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson´s disease within one-year follow-up. J Neurol 2008; 7:1059-1066 

  126. Hesse S, Barthel H, Strecker K, Oehlwein C, Sabri O, Schwarz J. Nuklearmedizinische Diagnostik beim Parkinson-Syndrom. Akt Neurol 2008; 35:389-398
  127. Wegner F, Kraft R, Busse K, Haertig W, Schwarz SC, Schaarschmidt G, Schwarz J, Hevers W. Functional and molecular analysis of GABAA receptors in human midbrain-derived neural progenitor cells. J Neurochem 2008 ; 107:1056-1069

  128. Focke A, Schwarz SC, Foerschler A, Scheibe J, Milosevic J, Zimmer C, Schwarz J. Labelling of human neural precursor cells using ferromagnetic nanoparticles. Magn Res Med 2008; 60:1321-1328

  129. Strecker K, Helm J, Meixensberger J, Schwarz J, Winkler D. Apraxia of Eye lid opening relieved by increase of frequeny in deep brain stimulation of the subthalamic nucleus in patients with Parkinson’s disease. Neurosurgery 2008; 63:E1204
  130. O'Brien JT, McKeith IG, Walker Z, Tatsch K, Booij J, Darcourt J, Marquardt M, Reininger C, DLB Study Group. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Brit J Psychiatry 2009; 194:34-39
  131. Dieterlen MT, Wegner F, Schwarz SC, Milosevic J, Schneider B, Busch M, Roemuss U, Brandt A, Storch A, Schwarz J. Non-viral gene tranfer by nucleofection allows stable gene expression in human neural progenitor cells. J Neurosci Meth 2009; 178:15-23
  132. Hesse S, Meyer P, Strecker K, Barthel H, Oehlwein C, Isaias IU, Schwarz J, Sabri O. Monoamine transporter availability in Parkinson’s disease patients with or without depression. Eur J Nucl Med Mol Imaging 2009; 36:428-435
  133. Schaarschmidt G, Schewtschik S, Kraft R, Wegner F, Eilers J, Schwarz J, Schmidt H. A new culturing strategy improves functional neuronal development of human neural progenitor cells. J Neurochem 2009; 109:238-247
  134. Hermann A, Suess C, Fauser M, Kanzler S, Witt M, Fabel K, Schwarz J, Höglinger GU, Storch A. Rostro-caudal gradual loss of cellular diversity within the periventricular regions of the caudal ventricular system. Stem Cells 2009; 27:928-941
  135. Milosevic J, Adler I, Manaenko A, Schwarz SC, Storch A, Schwarz J. Non-hypoxic stabilization of hypoxia-inducible factors: relevance in neural progenitor/stem cells. Neurotoxicity Res 2009; 15:367-80
  136. Grosset D, Antonini, A, Canesi, M, Pezzoli, G, Lees, A, Shaw, K, Cubo, E, Martinez-Martin, P, Rascol, O, Negres-Pages, L, Senard, A, Schwarz, J, Strecker, K, Reichmann, H, Storch, A, Loehle, M, Stocchi, F. Adherence to antiparkinson medication in a multi-centre European study. Mov Disord 2009; 24:826-32
  137. Rubini P, Milosevic J, Engelhardt J, Al-Khrasani M, Franke H, Heinrich A, Sperlagh B, Schwarz SC, Schwarz J, Nörenberg W, Illes P. Increase of intracellular Ca2+ by adenine and uracil nucleotides in human midbrain-derived neuronal progenitor cells. Cell Calcium 2009; 45:485-98
  138. Enard W, Gehre S, Hammerschmidt K, Hölter SM, Brückner MK, Schreiweis C, Winter C, Sohr R, Becker L, Wiebe V, Nickel B, Müller U, Groszer M, Adler T, Bolle I, Calzada-Wack J, Dalke C, Ehrhardt N, Favor J, Fuchs H, Gailus-Durner V, Hans W, Hölzlwimmer G, Javaheri A, Kallnik M, Kling E, Kunder S, Moßbrugger I, Racz I, Rathkolb B, Rozman J, Schrewe A, Busch DH, Graw J, Ivandic B, Kalaydjiev S, Klingenspor M, Klopstock T, Ollert M, Quintanilla-Martinez L, Schulz H, Wolf E, Wurst W, Zimmer A, Fisher SE, Morgenstern R, Arendt T, Hrabé de Angelis M, Fischer J, Schwarz J, Pääbo S. A humanized version of Foxp2 affects vocalization and neuronal functions in mice. Cell 2009; 137:961-71
  139. Milosevic J, Schwarz SC, Ogunlade V, Meyer AK, Storch A, Schwarz J. Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation. Mol Neurodegeneration 2009; 4:25
  140. Schaarschmidt G, Wegner F, Schwarz SC, Schmidt H, Schwarz J. Characterization of voltage-gated potassium channels in human neural progenitor cells. PloS ONE 2009; 4:e6168
  141. Meyer P, Strecker K, Kendziorra K, Becker GA, Hesse S, Woelpl D, Hensel A, Patt M, Sorger D, Wegner F, Lobsien D, Barthel H, Brust P, Gertz HJ, Sabri O, Schwarz J. Reduced α4β2* nicotinic acetylcholine receptor binding and its relationship to cognitive and depressive symptoms in Parkinson’s disease. Arch Gen Psychiatry 2009; 66:866-77
  142. Kraft E, Loichinger W, Diepers M, Lule D, Schwarz J, Ludolph AC, Storch A. Levodopa-induced striatal activation in Parkinson’s disease: A functional MRI study. Parkinsonism & Related Disorders 2009; 15:558-63. 
  143. Sabolek M, Baumann B, Heinrich M, Meyer AK, Herborg A, Liebau S, Maisel M, Hermann A, Herr A, Rubenwolf S, Schwarz J, Wirth T, Storch A. Initiation of dopaminergic differentiation of mesencephalic precursor cells depends on activation of multiple MAP kinase pathways. Stem Cells 2009; 27:2009-21 
  144. Wegner F Kraft R, Busse K, Schaarschmidt G, Härtig W, Schwarz SC, Schwarz J. Functional and molecular properties of glutamate receptors in human mesencephalic neural progenitor cells: NMDA enhances dopaminergic neurogenesis in vitro. J Neurochem 2009;111:204-16
  145. Lottaz C, Beier D, Meyer K, Herrmann A, Schwarz J, Oefner P, Bogdahn U, Wischhusen J, Spang R, Storch A, Beier CP. Transcriptional profiles of CD133+ and CD133- glioblastomaderived cancer stem cells indicate different cells of origin. Cancer Res 2010; 70:2030-40
  146. Schwarz SC, Schwarz J. Translation of stem cell therapy for neurological diseases. Transl Res 2010; 156:155-60
  147. Maisel M, Habisch HJ, Royer L, Herr A, Milosevic J, Hermann A, Liebau S, Brenner R, Schwarz J, Schroeder M, Storch A. Genome-wide expression profiling and functional network analysis upon neuroectodermal conversion of human mesenchymal stem cells suggest HIF-1 and miR-124a as important regulators. Exp Cell Res 2010: 316:2760-78
  148. Wolz M, Löhle M, Strecker K, Schwanebeck U, Schneider C, Reichmann H, Grählert X, Schwarz J, Storch A. Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized double-blind, placebo-controlled trial. J Neural Transm 2010; 117:1279-86
  149. Schwarz J. Nuclear medicine imaging in patients with Parkinson’s syndrome: an update. Nervenarzt 2010; 81:1160-67
  150. Strecker K, Wegner F, Hesse S, Becker GA, Patt M, Meyer PM, Lobsien D, Schwarz J, Sabri O. Preserved serotonin transporter binding in de novo Parkinson’s disease: negative correlation with the dopamine transporter. J Neurol 2011: 258:19-26
  151. Skardelly M, Gaber K, Burdack S, Scheidt F, Hilbig H, Boltze J, Förschler A, Schwarz J, Schwarz S, Meixensberger J, Schuhmann MU, Long term benefit of human fetal progenitor cell transplantation in a clinically adapted model after traumatic brain injury. J Neurotrauma 2011; 28:253-62
  152. Skardelly M, Gaber K, Schwarz J, Milosevic J. Neuroprotectgive effects of beta-catenine stabilization in an oxygen- and glucose-deprived human neural progenitor cell culture system. Int J Dev Neurosci 2011; 29:543-7
  153. Isaias IU, Marotta G, Pezzoli G, Sabri O, Schwarz J, Crenna P, Classen J, Cavallari P. Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. BMC Neurol. 2011; 11:88
  154. Loewenbrück K, Fuchs B, Hermann A, Brandt M, Werner A, Schwarz SC, Schöler HR, Schwarz J, Schiller J, Storch A. Proton MR spectroscopy of neural stem cells: Does the peak at 1.28 ppm function as a biomarker for cell type or state? Rejuvenation Res 2011; 14:371-81
  155. Braun M, Winkler D, Wehner M, Busch T, Schwarz J. Deep brain stimulation and general anesthesia. Basal Ganglia 2011; 1:79-82 
  156. Wegner F, Kraft R, Busse K, Härtig W, Leffler A, Dengler R, Schwarz J. Differentiated human midbrain-derived neural progenitor cells express excitatory strychnine-sensitive glycine receptors containing α2β subunits. PLoS One 2012; 7:e36946
  157. Synofzik M, Soehn AS, Gburek-Augustat J, Schicks J, Karle KN, Schüle R, Haack TB, Schöning M, Biskup S, Rudnik-Schöneborn S, Senderek J, Hoffmann KT, MacLeod P, Schwarz J, Bender B, Krüger S, Kreuz F, Bauer P, Schöls L. Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum. Orphanet J Rare Dis 2013;8:41
  158. Garrido-Vásquez P, Pell MD, Paulmann S, Strecker K, Schwarz J, Kotz SA. An ERP study of vocal emotion processing in asymmetric Parkinson's disease. Soc Cogn Affect Neurosci 2013; 8:918-27
  159. Hermann A, Loewenbrück KF, Boldt Ä, Fiedler C, Maisel M, Kalucka J, Schwarz J, Breier G, Storch A. Lack of vascular endothelial growth factor receptor-2/Flk1 signaling does not affect substantia nigra development. Neurosci Lett. 2013; 553:142-7
  160. Winkler D, Hammer N, Oehlwein C, Schwarz J, Strecker K, Fritzsch D, Meixensberger J. Implementing conventional Zamorano Dujovny frames versus individually manufactured microTargeting platforms--a comparative study on deep brain stimulation in Parkinson patients. Stereotact Funct Neurosurg 2013; 91:392-8
  161. Lojewski X, Hermann A, Wegner F, Araúzo-Bravo MJ, Hallmeyer-Elgner S, Kirsch M, Schwarz J, Schöler HR, Storch A. Human adult white matter progenitor cells are multipotent neuroprogenitors similar to adult hippocampal progenitors. Stem Cells Transl Med 2014; 3:458-69
  162. Busse K, Strotmann R, Strecker K, Wegner F, Devanathan V, Gohla A, Schöneberg T, Schwarz J. Adaptive gene regulation in the Striatum of RGS9-deficient mice. PLoS ONE 2014;9(3):e92605
  163. Eggert K, Öhlwein C, Kassubek J, Wolz M, Kupsch A, Ceballos-Baumann A, Ehret R, Polzer U, Klostermann F, Schwarz J, Fuchs G, Jost W, Albert A, Haag A, Hermsen A, Lohmüller K, Kuhn K, Wangemann M, Oertel WH. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol 2014; 37(4):116-22
  164. Matzke C, Lindner D, Schwarz J, Classen J, Hammer N, Weise D, Rumpf JJ, Fritzsch D, Meixensberger J, Winkler D. A comparison of two surgical approaches in functional neurosurgery: individualized versus conventional stereotactic frames. Comput Aided Surg. 2015; 20:34-40
  165. Lojewski X, Srimasorn S, Rauh J, Francke S, Wobus M, Taylor V, Araúzo-Bravo MJ, Hallmeyer-Elgner S, Kirsch M, Schwarz S, Schwarz J, Storch A, Hermann A. Perivascular mesenchymal Stem Cells from the adult Human brain harbor no Instrinsic neuroectodermal but high mesodermal differentiation potential. Stem Cells Transl Med. 2015; 4:1223-33
  166. Weise D, Hammer N, Rumpf JJ, Meixensberger J, Schwarz J, Winkler D. Unilateral multi-target deep brain stimulation in hemidystonia and hemichoreoathetosis following ischemic thalamic stroke. Basal Ganglia 2016; 6:153-156
  167. Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Mov Disord 2016; 31:1049-54
  168. Jochim A, Gempt J, Deschauer M, Schwarz J, Kirschke JS, Haslinger B. Status epilepticus after subthalamic deep brain stimulation surgery in a patient with Parkinson´s disease. World Neurosurg 2016: S1878-8750(16)30735-5
  169. Levin J, Maaß S, Schuberth M, Respondek G, Paul F, Mansmann U, Oertel WH, Lorenzl S, Krismer F, Seppi K, Poewe W, Wenning G; PROMESA study group, Giese A, Bötzel K, Höglinger G. The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. J Neural Transm 2016; 123:439-45
  170. Moon J, Schwarz SC, Lee HS, Kang JM, Lee YE, Kim B, Sung MY, Höglinger G, Wegner F, Kim JS, Chung HM, Chang SW, Cha KY, Kim KS, Schwarz J. Preclinical Analysis of Fetal Human Mesencephalic Neural Progenitor Cell Lines: Characterization and Safety In Vitro and In Vivo. Stem Cell Transl Med 2017; 6:576-588
  171. Alkemade A, de Hollander G, Keuken MC, Schäfer A, Ott DVM, Schwarz J, Weise D, Kotz SA, Forstmann BU. Comparison of T2*-weighted and QSM contrasts in Parkinson's disease to visualize the STN with MRI. PLoS One. 2017;12:e0176130
  172. Weber A, Schwarz SC, Tost J, Trümbach D, Winter P, Busato F, Tacik P, Windhorst AC, Fagny M, Arzberger T, McLean C, van Swieten JC, Schwarz J, Vogt Weisenhorn D, Wurst W, Adhikary T, Dickson DW, Höglinger GU, Müller U. Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1. Nat Commun. 2018; 9:2929
  173. Kim HW, Lee HS, Kang JM, Bae SH, Kim C, Lee SH, Schwarz J, Kim GJ, Kim JS, Cha DH, Kim J, Chang SW, Lee TH, Moon J. Dual Effects of Human Placenta-Derived Neural Cells on Neuroprotection and the Inhibition of Neuroinflammation in a Rodent Model of Parkinson's Disease. Cell Transplant. 2018; 27:814-830
  174. Rozanski V, Laux G, Schwarz J. The Dopamine Receptor Antagonism of Opipramol: Relevance to Parkinsonism? Clin Neuropharmacol. 2019; 42:77-79
  175. Jost WH, Lingor P, Tönges L, Schwarz J, Buhmann C, Kassubek J, Schrag A. Dyskinesia in multiple system atrophy and progressive supranuclear palsy. J Neural Transm (Vienna). 2019;126:925-932
  176. Levin J, Maaß S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, Südmeyer M, Eggert K, Mollenhauer B, Lipp A, Löhle M, Classen J, Münchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, Bötzel K, Ertl-Wagner B, Huppertz HJ, Ricard I, Höglinger GU, PROMESA Study Group. Lancet Neurol 2019; 18:724-735
  177. Reichmann H, Lees A, Rocha JF, Magalhães D, Soares-da-Silva P; OPTIPARK investigators. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener. 2020; 4:9
  178. Fauser M, Pan-Montojo F, Richter C, Kahle PJ, Schwarz SC, Schwarz J, Storch A, Hermann A. Chronic-Progressive Dopaminergic Deficiency Does Not Induce Midbrain Neurogenesis. Cells 2021; 10:775
  179. Kurz A, Kumar R, Northoff BH, Wenk C, Schirra J, Donakonda S, Höglinger GU, Schwarz J, Rozanski V, Hübner R, Bötzel K, Holdt LM, Koeglsperger T. Differential expression of gut miRNAs in idiopathic Parkinson's disease. Pakinsonism Relat Disord 2021; 88:46-50
  180. Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. Parkinsonism Relat Disord. 2022; 96:65-73
  181. Kim J, Inbo H, Kim HS, Kim W, Jang SJ, Min K, Kim SH, Bae SH, Jeong YH, Kim B, Kim C, Schwarz SC, Schwarz J, Cho KG, Chung SS, Moon J. First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells. Mov Disord 2023; 38: 589-603
  182. Weiss D, Ebersbach G, Möller JC, Schwarz J, Arlt C, Fritz B, Sensken SC, Eggert K. Do we start too late? Insights from the real-world non-interventional BALANCE study on the present use of levodopa/carbidopa intestinal gel in advanced Parkinson's disease in Germany and Switzerland. Parkinsonim Relat Didsord 2022; 103:85-91
  183. Hauser RA, Espay AJ, Ellenbogen AL, Fernandez HH, Isaacson SH, LeWitt PA, Ondo WG, Pahwa R, Schwarz J, Stocchi F, Zeitlin L, Banisadr G, Fisher S, Visser H, D'Souza R. IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial. JAMA Neurol 2023; 80:1062-69
  184. Greten S, Wegner F, Jensen I, Krey L, Rogozinski S, Fehring M, Heine J, Doll-Lee J, Pötter-Nerger M, Zeitzschel M, Hagena K, Pedrosa DJ, Eggers C, Bürk K, Trenkwalder C, Claus I, Warnecke T, Süß P, Winkler J, Gruber D, Gandor F, Berg D, Paschen S, Classen J, Pinkhardt EH, Kassubek J, Jost WH, Tönges L, Kühn AA, Schwarz J, Peters O, Dashti E, Priller J, Spruth EJ, Krause P, Spottke A, Schneider A, Beyle A, Kimmich O, Donix M, Haussmann R, Brandt M, Dinter E, Wiltfang J, Schott BH, Zerr I, Bähr M, Buerger K, Janowitz D, Perneczky R, Rauchmann BS, Weidinger E, Levin J, Katzdobler S, Düzel E, Glanz W, Teipel S, Kilimann I, Prudlo J, Gasser T, Brockmann K, Hoffmann DC, Klockgether T, Krause O, Heck J, Höglinger GU, Klietz M. The comorbidity and co-medication profile of patients with progressive supranuclear palsy. J Neurol 2024; 271:782-793
  185. Pürner D, Hormozi M, Weiß D, Barbe MT, Jergas H, Prell T, Gülke E, Pötter-Nerger M, Falkenburger B, Klingelhöfer L, Gutsmiedl PK, Haslinger B, Jochim AM, Wolff A, Schröter N, Rijntjes M, van Riesen C, Scheller U, Wolz M, Amouzandeh A, Ebersbach G, Gruber D, Kohl Z, Maetzler W, Paschen S, Pérez-González P, Rozanski V, Schwarz J, Südmeyer M, Torka E, Wesbuer S, Bornmann S, Flöel A, Ip CW, Krause P, Kühn AA, Csoti I, Herting B, van de Loo S, Basheer AA, Liszka R, Jost WH, Koschel J, Haller B, Lingor P. Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease. Neurology 2023; 101:e2078-93
  186. Jensen I, Stiel S, Bebermeier S, Schrag A, Greten S, Doll-Lee J, Wegner F, Ye L, Heine J, Krey L, Höllerhage M, Süß P, Winkler J, Berg D, Paschen S, Tönges L, Gruber D, Gandor F, Jost WH, Kühn AA, Claus I, Warnecke T, Pedrosa DJ, Eggers C, Trenkwalder C, Classen J, Schwarz J, Pötter-Nerger M, Kassubek J, Schnitzler A, Höglinger GU, Klietz M. A Short Progressive Supranuclear Palsy Quality of Life Scale. Mov Disord. 2024; 39:1602-1609
  187. Kassubek J, Jost WH, Schwarz J. Sublingual apomorphine in the treatment of Parkinson's disease. J Neural Transm. 2024; 131:1209-1216
  188. Kassubek J, Factor SA, Balaguer E, Schwarz J, Chaudhuri KR, Isaacson SH, Wu S, Denecke Muhr C, Kulisevsky J. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study. J Neurol. 2024; 271:3554-3570

Übersichtsarbeiten

  1. Tatsch K, Schwarz J, Kirsch CM. ZNS-SPECT: Rezeptorszintigraphie mit 123J-IBZM und 123J-Iomazenil. Der Nuklearmediziner 1993; 16:143-150

  2. Oertel WH, Schwarz J, Tatsch K, Arnold G, Gasser T, Kirsch CM. IBZM-SPECT as predictor for dopaminergic responsiveness of patients with de novo Parkinsonian syndrome. Advances of Neurology 1993; 60:519-524

  3. Schwarz J. Morbus Parkinson - Diagnostik und Verlauf. Quintessenz Medizin 1993; 3:219-227
  4. Bandmann O, Schwarz J. Morbus Parkinson - Therapie. Quintessenz Medizin 1993; 3:229-237 

  5. Vogl Th J, Steiner S, Hammerstingl R, Schwarz J, Kraft E, Weinzierl M, Felix R. MRT der Leber bei Morbus Wilson. Fortschr Röntgenstr 1994; 160:40-45

  6. Oertel WH, Trenkwalder C, Gasser T, Schwarz J, Bucher SF, Eichhorn T, Pogarell O, Künig G, Arnold G, Bandmann O, Dodel RC. Epidemiological, genetic, pharmacological, kinesiological, nuclear medical (IBZM-SPECT), standard and functional MRI studies on Parkinson's disease and related disorders and economic evaluation of Parkinson's disease therapy - clinical projects in the BMFT-research program Munich: "Parkinson's disease and other basal ganglia disorders". J Neural Transm (PD section) 1995; 46 Suppl:325-337

  7. Schwarz J. Reduktion der Levodopa-Dosis bei Morbus Parkinson. Extracta Geriatrica 1996; 5:24-25

  8. Schwarz J, Trenkwalder C. Restless Legs Syndrom: Therapie mit L-Dopa bzw. L-Dopa-Retardformen. Aktuelle Neurologie 1996; 23:26-29

  9. Schwarz J. Tremordominanter Morbus Parkinson: Therapie mit Dopamin-Agonisten. Psycho 1997; 23:446-449

  10. Schwarz J. The value of single photon emission computed tomography in the diagnosis of neurological disorders. Nervenheilkunde 1999; 18: 71-74

  11. Schwarz J. Morbus Parkinson – Pathophysiologische Mechanismen und Therapiestrategien. Psycho 2002; 28:466-471

  12. Storch A, Schwarz J. Neural stem cells and neurodegeneration. Curr Opin Invest Drugs 2002, 3:774-781

  13. Schwarz J, Reichmann H. Parkinson’s disease and neuroprotection: Dream or reality. Akt Neurol 2003; 30:51-58

  14. Schwarz J. Ratonale for dopamine agonist use as monotherapy in Parkinson’s disease. Curr Opin Neurol 2003; 16 Suppl. 1:S27-S33

  15. Müller T, Hefter H, Hueber R, Jost, WH, Leenders KL, Odin P, Schwarz J. Is levodopa toxic? J Neurol 2004 Suppl 6;

Deutsche Gesellschaft für Neurologie
Deutsche Parkinson Gesellschaft
Deutsche Gesellschaft für Klinische Neurophysiologie und Funktionelle Bildgebung

Klinische Forschung
Experimentelle Forschung
Gutachter für wissenschaftliche Zeitschriften
Gutachter für nationale und internationale Förderinstitutionen
Berater für Unternehmen der pharmazeutischen Industrie

Akutgeriatrie in der Kreisklinik Ebersberg: Spezialisierte Versorgung für ältere Patienten

Seit Sommer 2023 ist die bisherige Station Akutgeriatrie eine eigene Abteilung der Kreisklinik Ebersberg. Das geriatrisch ausgebildete Team unter der Leitung von Chefarzt Prof. Dr. Johannes Schwarz hat sich auf die Behandlung älterer Menschen mit internistischen, neurologischen Erkrankungen sowie unfallchirurgischen Verletzungen spezialisiert. Besonders hervorzuheben ist die Expertise von Prof. Schwarz in der Behandlung von Morbus Parkinson


Herausforderungen im Alter: Eigenständigkeit bewahren

Ältere Menschen sind nach einen Unfall oder eine Erkrankung oft stärker gefährdet, ihre Eigenständigkeit zu verlieren. Ein längerer Aufenthalt im Bett kann die Gehfähigkeit erheblich beeinträchtigen. Zudem steigen die Fallzahlen neurologischer Erkrankungen im Alter, die die Rückkehr zur Selbstständigkeit erschweren können, wenn sie nicht rechtzeitig behandelt werden.
 

Das Konzept der Akutgeriatrie Ebersberg

Die Abteilung Akutgeriatrie mit Parkinsonschwerpunkt in der Kreisklinik Ebersberg verfolgt ein innovatives Konzept. Durch den Einsatz moderner Diagnoseverfahren und intensiver Therapien, die Geriatrie-spezifischen Leitlinien folgen, wird die Lebensqualität älterer Patienten gefördert. Ziel ist es, die Fähigkeit zu erhalten oder wiederherzustellen, im eigenen Zuhause ohne Unterstützung leben zu können.

Ein interdisziplinäres Team aus Ärzten, spezialisierten Pflegekräften, Physiotherapeuten, Ergotherapeuten, Logopäden, Psychologinnen und dem Sozialdienst der Kreisklinik Ebersberg arbeiten eng zusammen, um optimale Behandlungsergebnisse zu erzielen.


Experte für Morbus Parkinson: Prof. Dr. Johannes Schwarz

Prof. Dr. Johannes Schwarz hat im Sommer 2023 seine Tätigkeit in der Kreisklinik Ebersberg aufgenommen und setzt einen besonderen Schwerpunkt auf die Behandlung von Morbus Parkinson. Mit jahrzehntelanger Forschungserfahrung an deutschen und internationalen Universitäten bringt er wertvolle Expertise in die Abteilung ein. Seine praktische Arbeit mit Patienten fließt direkt in seine Forschung ein, was die Behandlungsqualität erheblich steigert.
 

Diagnose und Therapie bei Morbus Parkinson

In der Kreisklinik Ebersberg werden alle verfügbaren diagnostischen und therapeutischen Möglichkeiten für die Behandlung von Morbus Parkinson eingesetzt und kontinuierlich weiterentwickelt. Neben medikamentösen Behandlungen liegt ein besonderes Augenmerk auf Lebensstilfaktoren wie Schlaf, Ernährung, Sport, Lebensfreude und Darmgesundheit, um die Lebensqualität der Patienten nachhaltig zu verbessern.

Kontaktieren Sie uns

Telefon
08092/82-10070

Fax
08092/82-2451

E-Mail
sophia.stettner@klinik-ebe.de

Sophia Stettner

Chefarztsekretärin
Sprechstunden ausblenden

Sprechstunden

Täglich 07:30 - 15:30 Uhr

Team der Akutgeriatrie mit Parkinsonschwerpunkt

Prof. Dr. J. Schwarz
Prof. Dr. med. Johannes Schwarz
Chefarzt der Akutgeriatrie & Parkinson
Zur Vita
Vita schliessen

1980Abitur, Wüllenweber Gymnasium, Bergneustadt
1981 - 1982Violoncello-Studium, Hochschule für Musik und darstellende Kunst, Wien
1982 - 1989Studium der Humanmedizin in Regensburg, Würzburg, Louisville und Boston
  

1989 - 1996Arzt in Weiterbildung, Neurologische Klinik, LMU Großhadern
1996 - 1998Oberarzt, Neurologische Klinik, Universität Ulm
1998 - 2001Visiting Associate Professor in Biology, California Institute of Neurology
2001 - 2011Professor und stv. Direktor, Neurologische Klinik, Universitätsklinik Leipzig und Visiting Associate, California Institute of Technology
2008 - 2011Gastprofessor, Pochon Cha Universität, Seoul, Südkorea
2009 - 2010Gastprofessor Université 3, Montpellier
2011 - 2023Chefarzt, Geriatrie und Parkinson-Schwerpunkt, Klinik Haag
seit 2023Chefarzt Abteilung Akutgeriatrie mit Parkinson-Schwerpunkt, Kreisklinik Ebersberg

1990Approbation
1996Facharzt Neurologie
1996Zusatzqualifikation Neurophysiologie
1997Zusatzqualifikation neurologische Intensivmedizin
1998Habilitation
2011Berufung als ordentlicher Professor

2000Richard-Heikkila-Preis der National Parkinson Foundation
2003Posterpreis der Deutschen Parkinson Gesellschaft 2003

Originalarbeiten

  1. Moessner J, Schwarz J, Fischbach W. Influence of "calcium2+-channel-blockers on exocrine pancreatic secretion by isolated rat acini. Res Exp Med Berl 1988; 188:255-265

  2. Gupta M, Schwarz J, Chen XL, Roisen FJ. Gangliosides prevent MPTP toxicity in mice - an immunocytochemical study. Brain Res 1990; 527:330-334

  3. Tatsch K, Schwarz J, Oertel WH, Kirsch CM. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 1991; 12: 699-707 

  4. Schwarz J, Trenkwalder C, Arnold G, Gasser T, Oertel WH. Folinic Acid Therapy Fails to Improve Early Parkinson's Disease: A Two Week Placebo Controlled Clinical Trial. J Neural Transm (PD section); 1992, 4: 35-41

  5. Schwarz J, Tatsch K, Vogl T, Arnold G, Trenkwalder C, Kirsch CM, Oertel WH. Marked reduction of striatal dopamine D2 receptors as detected by 123I-IBZM-SPECT in a Wilson's disease patient with generalized dystonia. Mov Disord 1992; 7:58-61

  6. Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, Oertel WH. 123I-Iodobenzamide-Spect predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992; 42:556-561

  7. Tatsch K, Schwarz J, Oertel WH, Kirsch CM. Idiopathic Parkinson Syndrome: I-123 IBZM SPECT findings in drug naive and treated patients. Eur J Nucl Med 1992; 19:556-561

  8. Oertel WH, Tatsch K, Schwarz J, Trenkwalder C, Scherer J, Weinzierl M, Kirsch CM. Reduction of striatal dopamine D2 receptors in 123I-IBZM-SPECT relates to neurological deficit in treated Wilson's disease. Ann Neurol 1992; 32: 743-748

  9. Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson syndromes. Arch Neurol 1992; 49:1131-1134 

  10. Schwarz J, Tatsch K, Arnold G, Ott M, Trenkwalder C, Kirsch CM, Oertel WH. 123I-Iodo-benzamide-Spect in 83 patients with de novo parkinsonism. Neurology 1993; 43 Suppl. 6: 17-20 

  11. Tatsch K, Schwarz J, Kirsch CM. ZNS-SPECT: Rezeptorszintigraphie mit 123J-IBZM und 123J-Iomazenil. Der Nuklearmediziner 1993; 16:143-150

  12. Baumert T, Kleber G, Schwarz J, Stabler A, Lamerz R, Mann K. Reversible hyperkinmesia in a patient with autoimmune polyglandular syndrome type-I. Clinical Investigator 2003; 71:924-927

  13. Arnold G, Bondy B, Bandmann O, Gasser T, Schwarz J, Trenkwalder C, Wagner M, Poewe W, Oertel WH. 3H-spiperone binding to lymphocytes fails in the differential diagnosis of de novo Parkinson syndromes. J Neural Transm {P-D Sect} 1993; 5:107-116 

  14. Oertel WH, Schwarz J, Tatsch K, Arnold G, Gasser T, Kirsch CM. IBZM-SPECT as predictor for dopaminergic responsiveness of patients with de novo Parkinsonian syndrome. Advances of Neurology 1993; 60:519-524

  15. Schwarz J, Antonini A, Kraft E, Tatsch K, Vogl T, Kirsch CM, Leenders KL, Oertel WH. Treatment with D-penicillamine improves dopamine D2 receptor binding and T2-signal intensity in de novo Wilson's disease. Neurology 1994; 44:1079-1082

  16. Arnold G, Trenkwalder C, Schwarz J, Oertel WH. Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug induced psychosis. Mov Disord 1994; 9:238-239

  17. Arnold G, Tatsch K, Oertel WH, Vogl Th, Schwarz J, Kraft E, Kirsch CM. Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI. J Neural Trans 1994; 42 Suppl.:111-118

  18. Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL. 11C-raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-DOPA and lisuride therapy on striatal dopamine D2 receptors. Neurology 1994; 44:1325-1329

  19. Schwarz J, Antonini A, Tatsch K, Kirsch CM, Oertel WH, Leenders KL. Comparison of 123I-IBZM-SPECT and 11C-raclopride-PET findings in patients with parkinsonism. Nucl Med Comm 1994; 15:806-813

  20. Scherer J, Tatsch K, Schwarz J, Oertel WH, Kirsch CM, Albus M. Striatal D2 dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biol Psych 1994; 36:627-629

  21. Scherer J, Tatsch K, Schwarz J, Oertel WH, Konjarczyk M, Albus M. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Scand 1994; 90:266-268

  22. Vogl Th J, Steiner S, Hammerstingl R, Schwarz J, Kraft E, Weinzierl M, Felix R. MRT der Leber bei Morbus Wilson. Fortschr Röntgenstr 1994; 160:40-45

  23. Trenkwalder C, Stiasny K, Pollmächer T, Wetter T, Schwarz J, Kohnen R, Katzenwadl J, Krüger HP, Ramm S, Künzel M, Oertel WH. L-DOPA therapy of uremic and idiopathic restless legs syndrome: a double blind, crossover trial. Sleep 1995, 18:681-688

  24. Trenkwalder C, Schwarz J, Gebhard J, Ruland D, Trenkwalder P, Hense HW, Oertel WH. Starnberg trial on epidemiology of parkinsonism and hypertension in the elderly: prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 1995; 52:1017-1022

  25. Schwarz TF, Pfister HW, Schwarz J, Pauli C, Jäger G. Meningitis nach Aufenthalt im Mittelmeerraum, durch Sandfliegenvirus verursacht. Nervenarzt 1995; 66:789-791

  26. Oertel WH, Trenkwalder C, Gasser T, Schwarz J, Bucher SF, Eichhorn T, Pogarell O, Künig G, Arnold G, Bandmann O, Dodel RC. Epidemiological, genetic, pharmacological, kinesiological, nuclear medical (IBZM-SPECT), standard and functional MRI studies on Parkinson's disease and related disorders and economic evaluation of Parkinson's disease therapy - clinical projects in the BMFT-research program Munich: "Parkinson's disease and other basal ganglia disorders". J Neural Transm (PD section) 1995; 46 Suppl:325-337

  27. Gerlach M, Götz M, Dirr A, Kupsch A, Janetzky B, Oertel W, Sautter J, Schwarz J, Reichmann H, Riederer P. Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin. Neurochem Int 1996; 28:41-49 

  28. Schwarz J, Weis S, Kraft E, Tatsch K, Bandmann O, Mehrain P, Vogl T, Oertel WH. Signal changes on MRI and increase of reactive micro-, astrogliosis and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 1996; 60:98-101 

  29. Schwarz J, Oertel, WH, Tatsch K. Iodine-123-iodobenzamide binding in parkinsonism: Reduction by dopamine agonists but not L-Dopa. J Nucl Med; 1996; 37:1112-1115

  30. Eichhorn T, Gasser T, Mai N, Marquardt C, Arnold G, Schwarz J, Oertel WH. Computational analysis of automated handwriting movements: a rapid method to detect dopamimetic effects in Parkinson's disease. Mov Disord 1996; 11:289-297 

  31. Kupsch A, Sautter J, Schwarz J, Gerlach M, Riederer P, Oertel WH. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 1996; 741:185-196

  32. Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Long term changes of dopamine D2 receptors in patients with Parkinson's disease: a study with PET and [11C]raclopride. Mov Disord 1997; 12:33-38

  33. Scheidtmann K, Schwarz J, Holinski-Feder E, Gasser Th, Trenkwalder C. Paroxysmal choreoathetosis - a disorder related to Huntington's disease. J Neurol 1997; 244:395-398

  34. Schwarz J, Scheidtmann K, Trenkwalder C. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa. Eur Neurol 1997; 37:236-238

  35. Schwarz J, Planck J, Briegel J, Straube A. Single-fiber electromyography, nerve conduction studies and conventional electromyography in patients with critical-illness polyneuropathy: evidence for a lesion of terminal motor axons. Muscle Nerve 1997; 20:696-701

  36. Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, Fieber RS, Hahn K, Kung HF. Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997; 24:415-421

  37. Scherer J, Tatsch K, Albus M, Schwarz J, Mager T, Oertel WH. Dopamine D2 receptor occupancy during treatment with haloperidol decanoate. Eur Arch Psychiatry Clin Neurosci 1997; 247:104-106 

  38. Welz A, Pogarell O, Tatsch K, Schwarz J, Cryssagis K, Reichart B. Surgery of the thoracic aorta using deep hypothermic total circulatory arrest. Are there neurological consequences other than frank cerebral defects. Eur J Cardiothorac Surg 1997; 11:650-656

  39. Plaschke M, Schwarz J, Dahlheim H, Backmund H, Trenwalder C. Cardiovascular and renin responses to head-up tilt test in parkinsonism. Acta Neurol Scan 1997;.96: 206-210

  40. Schwarz J, Kornhuber M, Bischoff C, Straube A. Electromyography of the external anal sphincter in patients with Parkinson' disease and multiple system atrophy. Muscle Nerve 1997; 20:1167-1172

  41. Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH. 123I-IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Mov Disord 1997; 12:898-902

  42. Kupsch A, Pogarell O, Schwarz J, Straube A, Oertel WH Tatsch K, Linke R. Parkinson’s disease and tumor in the SMA, a re-evaluation. J Neurol Neurosurg Psychiatry 1997; 63:811-812 

  43. Arnold G, Schwarz J, Macher C, Oertel WH. Domperidone is superior to ondansetron in acute apomorphine challenge in previously untreated parkinsonian patients - a double blind study. Parkinsonism & Related Disorders 1997; 3:191-193 

  44. Schwarz J, Tatsch K, Gasser T, Arnold G, Pogarell O, Künig G, Oertel WH. 123I-IBZM binding compared to long term clinical follow up in patients with de novo parkinsonism. Mov Disord 1998; 13:16-19 

  45. Schwarz SC, Schwarz J, Sautter J, Oertel WH, Effects of macrophage migration inhibitory factor and macrophage migration stimulatory factor on function and survival of foetal dopaminergic grafts in the 6-hydroxydopamine model of Parkinson´s disease. Exp Brain Res 1998; 120: 95 -103 
  46. Götz ME, Breithaupt W, Sautter J, Kupsch A, Schwarz J, Oertel WH, Youdim MBH, Riederer P, Gerlach M. Chronic TVP-1012 (rasagiline) dose - activity response of monoamine oxidases A and B in the brain of the common marmoset. J Neural Transm 1998; 52 Suppl.:271-278

  47. Borasio GD, Linke R, Schwarz J, Schlamp V, Abel A, Mozley PD, Tatsch K. Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT-SPECT. J Neurol Neurosurg Psychiatry 1998; 65:263-265

  48. Schwarz J, Scherer J, Trenkwalder C, Mozley PD, Tatsch K. Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy? Psychiatry Res: Neuroimaging 1998; 83:23-28 

  49. Schwarz SC, Seufferlein T, Liptay S, Schmid RM, Kasischke K, Foster OJF, Daniel S, Schwarz J. Microglial activation in multiple system atrophy: a potential role for NF-kappaB/Rel Proteins. Neuroreport 1998; 9:3029-3032

  50. Kraft E, Schwarz J, Gasser T, Arnold G, Pfluger T, Oertel WH. The combination of hypointense and hyperintense signal changes in the basal ganglia is specific for multiple system atrophy. Arch Neurol 1999; 56: 125-128

  51. Schwarz J, Kraft E, Vogl T, Arnold G, Tatsch K, Oertel WH. Relative quantification of signal on T2-weighted MRI images in the basal ganglia: Limited value in differential diagnosis of patients with parkinsonism. Neuroradiol; 1999; 41: 124-127 

  52. Storch A, Ludolph AC, Schwarz J. HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpyridine (MPP+) via impairment of energy metabolism. Neurochem Int 1999; 35:393-403 

  53. Sperfeld AD, Collatz MB, Baier H, Palmbach M, Storch A, Schwarz J, Tatsch K, Reske SN, Joosse M, Heutink P, Ludolph AC. FTDP-17: An early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol 1999; 46:708-715  

  54. Storch A, Kaftan A, Burkhardt K, Schwarz J. 1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism. Brain Res 2000; 855:67-75

  55. Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T, Tatsch K. Striatal dopamine transporter binding assessed by [I-123] IPT and single photon emission tomography in patients with early Parkinson’s disease: Implications for a preclinical diagnosis. Arch Neurol 2000; 57:205-208

  56. Storch A, Blessing H, Bareis M, Jankowski S, Schwarz J. Catechol-O-methyl transferase (COMT) inhibition enantio-selectively attenuates levodopa toxicity in primary dopaminergic neurons in vitro. Mol Pharmacol 2000; 57:589-594

  57. Storch A, Kaftan A, Burkhardt K, Schwarz J. Cytotoxicity of 6-hydroxydopamine towards human SH-SY5Y dopaminergic neuroblastoma cells is independent from energy metabolism. J Neural Transm PD Section 2000; 107: 281-293 

  58. Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic REM sleep behavior disorder: comparison to Parkinson’s disease and controls. Brain; 2000; 123:1155-1160

  59. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MH, Sips HJ, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000; 15:503-510 

  60. Storch A, Burkhardt K, Ludolph AC, Schwarz J. Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J Neurochem. 2000 75:2259-2269 

  61. Labarca, C., Schwarz J, Deshpande, P., Schwarz, S., Nowak, M.W., Fonck, C., Nashmi, R., Kofuji, P., Dang, H., Shi, W., Fidan, M., Khakh, B.S., Chen, Z., Bowers, B.J., Boulter, J., Wehner, J.M., and Lester, H.A. Point mutant mice with hypersensitive 4 nicotinic receptors show dopaminergic deficits and increased anxiety.  PNAS 2001, 98:2786-2791

  62. Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. Nucl Med Commun 2001; 22:721-725 

  63. Storch A, Paul G, Csete M, Boehm BO, Carvey PM, Kupsch A, Schwarz J. Long-term proliferation and dopaminergic differentiation of human mesencephalon-derived neural precursor cells. Exp Neurol 2001; 170:317-325

  64. Kraft E, Schwarz J, Trenkwalder C, Oertel WH. Hyperintense lateral rim and hypointense putamen are typical but not exclusive of multiple system atrophy - In reply. Arch Neurol 2001; 58:1026

  65. Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MBH, Riederer P, Gerlach M, Oertel WH. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegeline. J Neural Transm 2001; 108:985-1009

  66. Storch A, Ott S, Hwang YI, Ortmann R, Hein A, Frenzel S, Matsubara K, Collins M, Ohta S, Wolf HU, Schwarz J. Selective dopaminergic toxicity of isoquinoline derivatives related to Parkinson’s disease: studies using heterologous expression systems of the dopamine transporter. Biochem Pharmacol 2002; 63:909-920

  67. Arnold G, Tatsch K, Kraft E, Bandmann O, Wächter T, Oertel WH, Schwarz J. Steele-Richardson-Olszewski syndrome: relation of dopamine D2 receptor binding and subcortical lesions in MRI. J Neural Transm 2002; 109:503-512

  68. Storch A, Schwarz J. Neural stem cells and neurodegeneration. Curr Opin Invest Drugs 2002, 3:774-781

  69. Arnold G, Tatsch K, Kraft E, Bandmann O, Wächter T, Oertel WH, Schwarz J. Steele-Richardson-Olszewski syndrome: Reduction of dopamine D2 receptor binding relates to the severity of midbrain atrophy in vivo - an IBZM-SPECT and MRI study. Mov Disord 2002; 17:557-562

  70. Lehmensiek V, Tan EM, Schwarz J, Storch A. Expression of mutant alpha-synuclein enhances dopamine transporter mediated MPP+ toxicity in HEK 293 cells. NeuroReport 2002;13:1279-83

  71. Blessing H, Bareiss M, Zettlmeisl H, Schwarz J, Storch A. Catechol-O-methyltransferase inhibition protects against 3,4-dihydroxyphenylalanine (DOPA) toxicity in primary mesencephalic cultures: new insights into levodopa toxicity. Neurochem Int 2003; 42:139-151

  72. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Hauser RA, Poewe WH, Brooks DJ, REAL-PET Study group. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54:93-101 

  73. Fonck C, Nashmi R, Deshpande P, Marks MJ, Riedel A, Schwarz J, Collins AC, Labarca C, Lester HA. Increased sensitivity to agonist-induced seizures and Straub tal in knock-in mice carrying hypersensitive a4 nicotinic receptors. J Neurosci 2003; 23:2582-2590

  74. Eisensehr I, Linke R, Tatsch K. Kharraz B, Gildehaus JF, Wetter CT, Trenkwalder C, Schwarz J, Noachter S. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep 2003; 26:507-12

  75. Gerhard A, Banati R, Goerres GB, Cagnin A, Myers R, Gunn RN, Turkheimer F, Good CD, Mathias CJ, Quinn N, Schwarz J, Brooks DJ. [11C](R)PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 2003; 61:686-9 

  76. Rahman Z, Schwarz J, Wein M, Gold SJ, Kovoor A, Chen CK, Self D, Neve RL, Schwarz SC, Lester HA, Simon MI, Nestler EJ. RGS9 modulates dopamine signaling in the basal ganglia. Neuron. 2003; 38:941-52 (Rahman and Schwarz contributed equally) 

  77. Storch A, Lester HA, Boehm BO, Schwarz J. Functional characterization of dopaminergic neurons derived from murine mesencephalic stem cells. J Chem Neuroanat 2003; 26:133-42

  78. Milosevic J, Storch A, Schwarz J. Spontaneous apoptosis in murine free floating neurospheres. Exp Cell Res 2004; 294:9-17 

  79. Storch A, Hwang YI, Gearhart DA, Beach JW, Neafsey EJ, Collins MA, Schwarz J. Dopamine transporter-mediated cytotoxicity of ß-carbolinium derivatives related to Parkinson’s disease: relationship to transporter-dependent uptake. J Neurochem 2004; 89:685-694

  80. Pöpperl G, Ruzicka E, Storch A, Gasser T, Tatsch K, Schwarz J. Comparison of α-dihydroergocryptine and levodopa monotherapy in Parkinson’s disease: assessment of disease progression with [123I]IPT SPECT. J Neural Transm 2004; 111:1041-1052

  81. Günther P, Storch A, Schwarz J, Sabri O, Steinbach P, Wagner A, Hesse S. Basal ganglia involvement of a patient with SCA 17 – a new form of autosomal dominant spinocerebellar ataxia. J Neurol 2004; 251:896-897

  82. Orb S, Wieacker J, Labarca C, Fonck C, Lester HA, Schwarz J. Knockin mice with Leu9'Ser alpha4-nicotinic receptors: substantia nigra dopaminergic neurons are hypersensitive to agonist and lost postnatally. Physiol Genomics 2004; 18:299-307 

  83. Hermann A, Gastl R, Fiedler J, Liebau S, Popa MO, Boehm BO, Lerche H, Schwarz J, Brenner R, Storch A. Efficient generation of neural stem cells from adult human bone marrow stromal cells. J Cell Sci 2004; 117:4411-4422

  84. Storch A, Sabolek M, Milosevic J, Schwarz SC, Schwarz J. Midbrain-derived neural stem cells: from basic science to therapeutic options. J Cell Tiss Res 2004; 318:15-22 

  85. Schwarz J, Storch A, Pogarell O, Tatsch K. Striatal dopamine transporter binding in Parkinson’s disease: follow up for 7.5 years. J Nucl Med 2004; 45:1694-1697

  86. Storch A, Ludolph AC, Schwarz J. Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J Neural Transm 2004; 111:1267-1286

  87. Tapper A, McKinney SS, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA. Nicotine activation of α4 receptors is sufficient for reward, tolerance and sensitization. Science 2004; 306:1029-1032

  88. Hesse S, Barthel H, Schwarz J, Sabri O, Müller U. Advances in in-vivo imaging of serotonergic neurons in neurological diseases with affective disorders. Neuroscience and Biobehavioral Reviews 2004; 28:547-563

  89. Gerhard A, Schwarz J, Myers R, Wise R, Banati R. Evolution of microglial activation in patients after ischemic stroke: A [11C] (R)-PK11195 PET study. NeuroImage 2005; 15:282-290

  90. Storch A, Kornhass M, Schwarz J. Acanthocytosis: reference values for dry, wet and diluted smears. J Neurol 2005; 252:84-90

  91. Kovoor A, Seyffarth P, Ebert J, Barghshoon S, Chen CK, Schwarz SC, Axelrod JD, Simon MI, Lester HA, Schwarz J. D2 dopamine receptors colocalize RGS9 2 via the RGS9 DEP domain and RGS9 knockout mice develop dyskinesias associated with dopamine pathways. J Neurosci 2005; 25:2157-2165

  92. Milosevic J, Schwarz SC, Krohn K, Poppe M, Storch A, Schwarz J. Low atmospheric oxygen avoids maturation, senescence and cell death of murine mesencephalic neural precursors. J Neurochem 2005; 92:718-729

  93. Milosevic J, Storch A, Schwarz J. Cryopreservation does not affect proliferation and multipotency of murine neural precursor cells. StemCells 2005; 23:681-688 

  94. Winkler D, Tittgemeyer M, Schwarz J, Strecker K, Gielen F, Strauss G, Lindner D, Meixensberger J. Evaluation of brain shift during neurosurgical biopsies guided by interventional magnetic resonance imaging. J Neurol Neurosurg Psychiatr 2005; 76:1161-3

  95. Arnold G, Gasser T, Storch A, Lipp A, Kupsch A, Hundemer HP, Schwarz J. High doses of pergolide are efficacious and safe in progressed Parkinson’s disease. Arch Gerontol Geriatrics 2005; 41:239-251

  96. Storch A, Trenkwalder C, Oehlwein C, Winkelmann J, Polzer U, Hundemer HP, Schwarz J. High-dose treatment with pergolide in Parkinson’s disease patients with motor fluctuations and dyskinesias. Parkinsonism & Rel Disord 2005; 11:393-398 

  97. Oertel WH, Wolters EC, Sampiao C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset DG, Arnold G, Leenders KL, Hundemer HP, Lledo A, Wood A, Frewer P, Schwarz J. Pergolide versus L-Dopa monotherapy in early Parkinson’s disease patients: the Pelmopet* study. Mov Disord 2006; 21:343-353 

  98. Lehmensiek V, Tan EM, Liebau S, Lenk T, Zettlmeisl H, Schwarz J, Storch A. Dopamine tranporter mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant α-synucleins related to Parkinson’s disease. Neurochem Int 2006; 48:329-340 

  99. Schneider JP, Reinohs M, Prothmann S, Puccini S, Dalitz B, Schwarz J, Zimmer C, Then Bergh F. Subcortical right parietal AVM: rotational vertigo and caloric stimulation fMRI support a parietal representation of vestibular input. J Neurol 2006; 253:253-5

  100. Schwarz J, Schwarz SC, Dorigo O, Stuetzer A, Wegner F, Labarca C, Deshpande P, Gil JS, Berk AJ, Lester HA. Enhanced expression of hypersensitive α4 nAChR in adult mice increases the loss of midbrain dopaminergic neurons. FASEB J, 2006; 20:935-46 

  101. Hermann A, Maisel M, Liebau S, Kim DW, Wegner F, Gerlach M, Schwarz J, Kim KS, Storch A. Multipotent neural stem cells from the adult tegmentum differentiate into functional dopamineregic neurons. StemCells 2006; 24:949-64 

  102. Milosevic J, Juch F, Storch A, Schwarz J. Low extracellular calcium is sufficient for survival and proliferation of murine mesencephalic neural precursor cells. Cell Tiss Res 2006; 324:377-84 

  103. Storch A, Heimhilger E, Schwarz J. Increased periodontal pathology in Parkinson’s disease. J Neurol 2006; 253:608-611

  104. Schwarz SC, Wittlinger J, Schober R, Storch A, Schwarz J. Transplantation of human neural precursor cells in the 6-OHDA lesioned rats: effect of immunosuppression with Cyclosporine A. Parkinsonism & Rel Disord 2006; 12:302-308

  105. Hermann A, Liebau S, Gastl R, Fickert S, Habisch HJ, Fiedler J, Schwarz J, Brenner R, Storch A. Comparative analysis of neuroectodermal differentiation capacity of human bone marrow stromal cells using various conversion protocols. J Neurosci Res 2006; 83:1502-151

  106. Seeman P, Schwarz J, Chen JF, Szechtman H, Perrault M, McKnight GS, Roder JC, Quirion R, Boksa P, Srivastava LK, Yanai K, Weinshenker D, Sumiyoshi T. Psychosis pathways converge via D2High dopamine receptors. Synapse 2006; 60:319-346 

  107. Hermann A, Maisel M, Liebau S, Gerlach M, Kleger A, Schwarz J, Kim KS, Antoniadis G, Lerche H, Storch A. Mesodermal cell types induce neurogenesis from adult human hippocampal progenitor cells. J Neurochem 2006; 98:629-40

  108. Then Bergh F, Niklas A, Strauss A, von Ahsen N, Niederwieser D, Schwarz J, Wagner A, Haifa AA. Rapid progression of myelodysplastic syndrome to acute myeloid leukemia on sequential azathioprine, IFN beta and copolymer-1 treatment in a patient with multiple sclerosis. Acta Haematol 2006; 116:207-10

  109. Sabolek M, Herborg A, Schwarz J, Storch A. Dexamethasone blocks astroglial but not neuronal differentiation from rat mesencephalic neural precursors. NeuroReport 2006; 17:1719-1723

  110. Strecker K, Schneider JP, Barthel H, Hermann W, Wegner F, Schwarz J, Sabri O, Zimmer C. Profound Midbrain Atrophy in Patients with Wilson’s Disease and Neurological Symptoms? J Neurol 2006; 253:1024-1029

  111. Hesse S, Oehlwein C, Barthel H, Schwarz J, Polster D, Wagner A, Sabri O. Possible impact of dopamine SPECT on decision-making for drug treatment in parkinsonian syndrome. J Neur Transm 2006;  113:1177-1190

  112. Milosevic J, Brandt A, Roemuss U, Arnold A, Wegner F, Schwarz SC, Storch A, Zimmermann H, Schwarz J. Uracil nucleotides stimulate human neural precursor cell proliferation and dopaminergic differentiation: Involvement of MEK-ERK signalling. J Neurochem 2006; 99:913–923

  113. Storch A, Hwang YI, Bringmann G, Ott S, Brueckner R, Schwarz J. Cytotoxicity of chloral derived b–carbolines in neuroblastoma cells and heterologous expression systems of the dopamine transporter. J Neural Transm 2006; 113:1895-1901 

  114. Milosevic J, Maisel M, Wegner F, Leuchtenberger J, Wenger RH, Gerlach M, Storch A, Schwarz J. Lack of HIF-1α impaires midbrain neural precursor cells involving VEGF signalling. J Neurosci 2007; 27:412-421

  115. Strecker K, Schneider JP, Sabri O, Wegner F, Then Bergh F, Schwarz J, Hesse S. Responsiveness to a dopamine agonist in Holmes tremor – Case report. Eur J Neurol 2007; 14:e9-e10

  116. Winkler D, Strauss G, Helm J, Goldammer A, Schneider JP, Schwarz J, Meixensberger J. MicroTargeting® platform: an individual stereotaxic device in functional neurosurgery. Int J CARS 2007; 1:295-299

  117. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, Padovani A, Giubbini R, Bonuccelli U, Volterrani D, Holmes C, Kemp P, Tabet N, Meyer I, Reininger C; DLB Study group. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007; 4:305-313

  118. Maisel M, Herr A, Milosevic J, Hermann A, Habisch HJ, Schwarz SC, Kirsch M, Antoniadis G, Brenner R, Hallmeyer-Elgner S, Lerche H, Schwarz J, Storch A. Transcription profiling of adult and fetal human neuroprogenitors identifies divergent paths to maintain the neuroprogenitor cell state. Stem Cells 2007; 5:1231-40

  119. Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, Oertel WH, Tolosa E, Lees AJ, Poewe W. Role of DAT-SPECT in the diagnostic work-up of parkinsonism. Mov Disord 2007, 22:1229-38 

  120. Milosevic J, Schwarz SC, Poppe M, Dieterlen M, Maisel M, Storch A, Schwarz J. Dopamine D3 receptor stimulation fails to promote dopaminergic neurogenesis of murine and human midbrain derived neural precursor cells in vitro. Stem Cells Dev 2007. 16:625-635

  121. Strecker K, Schneider JP, Wegner F, Hesse S, Schwarz J. Eye of the Tiger sign in Multiple System Atrophy - Case Report. Eur J Neurol 2007; 11:e1-2 

  122. Wegner F, Strecker K, Schwarz J, Wagner A, Heinritz W, Sommerer F, Thal DR, Schneider JP, Kendziorra K, Sabri O. Vascular parkinsonism and dementia in a CADASIL case with intact nigrostriatal dopaminergic system. J Neurol 2007; 254:1743-1745

  123. Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T; ADVANS Study Group. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol 2008; 65:577-583

  124. Sabolek M, Mieskes I, Lenk T, Lehmensiek V, Schwarz J, Storch A. Stage-dependent vulnerability of fetal mesencephalic neuroprogenitors towards dopaminergic neurotoxins. Neurotoxicology 2008; 4:714-721 

  125. Hesse S, Strecker K, Winkler D, Luthardt J, Scherfler C, Reupert A, Oehlwein C, Barthel H, Schneider JP, Wegner F, Meyer P, Meixensberger J, Sabri O, Schwarz J. Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson´s disease within one-year follow-up. J Neurol 2008; 7:1059-1066 

  126. Hesse S, Barthel H, Strecker K, Oehlwein C, Sabri O, Schwarz J. Nuklearmedizinische Diagnostik beim Parkinson-Syndrom. Akt Neurol 2008; 35:389-398
  127. Wegner F, Kraft R, Busse K, Haertig W, Schwarz SC, Schaarschmidt G, Schwarz J, Hevers W. Functional and molecular analysis of GABAA receptors in human midbrain-derived neural progenitor cells. J Neurochem 2008 ; 107:1056-1069

  128. Focke A, Schwarz SC, Foerschler A, Scheibe J, Milosevic J, Zimmer C, Schwarz J. Labelling of human neural precursor cells using ferromagnetic nanoparticles. Magn Res Med 2008; 60:1321-1328

  129. Strecker K, Helm J, Meixensberger J, Schwarz J, Winkler D. Apraxia of Eye lid opening relieved by increase of frequeny in deep brain stimulation of the subthalamic nucleus in patients with Parkinson’s disease. Neurosurgery 2008; 63:E1204
  130. O'Brien JT, McKeith IG, Walker Z, Tatsch K, Booij J, Darcourt J, Marquardt M, Reininger C, DLB Study Group. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Brit J Psychiatry 2009; 194:34-39
  131. Dieterlen MT, Wegner F, Schwarz SC, Milosevic J, Schneider B, Busch M, Roemuss U, Brandt A, Storch A, Schwarz J. Non-viral gene tranfer by nucleofection allows stable gene expression in human neural progenitor cells. J Neurosci Meth 2009; 178:15-23
  132. Hesse S, Meyer P, Strecker K, Barthel H, Oehlwein C, Isaias IU, Schwarz J, Sabri O. Monoamine transporter availability in Parkinson’s disease patients with or without depression. Eur J Nucl Med Mol Imaging 2009; 36:428-435
  133. Schaarschmidt G, Schewtschik S, Kraft R, Wegner F, Eilers J, Schwarz J, Schmidt H. A new culturing strategy improves functional neuronal development of human neural progenitor cells. J Neurochem 2009; 109:238-247
  134. Hermann A, Suess C, Fauser M, Kanzler S, Witt M, Fabel K, Schwarz J, Höglinger GU, Storch A. Rostro-caudal gradual loss of cellular diversity within the periventricular regions of the caudal ventricular system. Stem Cells 2009; 27:928-941
  135. Milosevic J, Adler I, Manaenko A, Schwarz SC, Storch A, Schwarz J. Non-hypoxic stabilization of hypoxia-inducible factors: relevance in neural progenitor/stem cells. Neurotoxicity Res 2009; 15:367-80
  136. Grosset D, Antonini, A, Canesi, M, Pezzoli, G, Lees, A, Shaw, K, Cubo, E, Martinez-Martin, P, Rascol, O, Negres-Pages, L, Senard, A, Schwarz, J, Strecker, K, Reichmann, H, Storch, A, Loehle, M, Stocchi, F. Adherence to antiparkinson medication in a multi-centre European study. Mov Disord 2009; 24:826-32
  137. Rubini P, Milosevic J, Engelhardt J, Al-Khrasani M, Franke H, Heinrich A, Sperlagh B, Schwarz SC, Schwarz J, Nörenberg W, Illes P. Increase of intracellular Ca2+ by adenine and uracil nucleotides in human midbrain-derived neuronal progenitor cells. Cell Calcium 2009; 45:485-98
  138. Enard W, Gehre S, Hammerschmidt K, Hölter SM, Brückner MK, Schreiweis C, Winter C, Sohr R, Becker L, Wiebe V, Nickel B, Müller U, Groszer M, Adler T, Bolle I, Calzada-Wack J, Dalke C, Ehrhardt N, Favor J, Fuchs H, Gailus-Durner V, Hans W, Hölzlwimmer G, Javaheri A, Kallnik M, Kling E, Kunder S, Moßbrugger I, Racz I, Rathkolb B, Rozman J, Schrewe A, Busch DH, Graw J, Ivandic B, Kalaydjiev S, Klingenspor M, Klopstock T, Ollert M, Quintanilla-Martinez L, Schulz H, Wolf E, Wurst W, Zimmer A, Fisher SE, Morgenstern R, Arendt T, Hrabé de Angelis M, Fischer J, Schwarz J, Pääbo S. A humanized version of Foxp2 affects vocalization and neuronal functions in mice. Cell 2009; 137:961-71
  139. Milosevic J, Schwarz SC, Ogunlade V, Meyer AK, Storch A, Schwarz J. Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation. Mol Neurodegeneration 2009; 4:25
  140. Schaarschmidt G, Wegner F, Schwarz SC, Schmidt H, Schwarz J. Characterization of voltage-gated potassium channels in human neural progenitor cells. PloS ONE 2009; 4:e6168
  141. Meyer P, Strecker K, Kendziorra K, Becker GA, Hesse S, Woelpl D, Hensel A, Patt M, Sorger D, Wegner F, Lobsien D, Barthel H, Brust P, Gertz HJ, Sabri O, Schwarz J. Reduced α4β2* nicotinic acetylcholine receptor binding and its relationship to cognitive and depressive symptoms in Parkinson’s disease. Arch Gen Psychiatry 2009; 66:866-77
  142. Kraft E, Loichinger W, Diepers M, Lule D, Schwarz J, Ludolph AC, Storch A. Levodopa-induced striatal activation in Parkinson’s disease: A functional MRI study. Parkinsonism & Related Disorders 2009; 15:558-63. 
  143. Sabolek M, Baumann B, Heinrich M, Meyer AK, Herborg A, Liebau S, Maisel M, Hermann A, Herr A, Rubenwolf S, Schwarz J, Wirth T, Storch A. Initiation of dopaminergic differentiation of mesencephalic precursor cells depends on activation of multiple MAP kinase pathways. Stem Cells 2009; 27:2009-21 
  144. Wegner F Kraft R, Busse K, Schaarschmidt G, Härtig W, Schwarz SC, Schwarz J. Functional and molecular properties of glutamate receptors in human mesencephalic neural progenitor cells: NMDA enhances dopaminergic neurogenesis in vitro. J Neurochem 2009;111:204-16
  145. Lottaz C, Beier D, Meyer K, Herrmann A, Schwarz J, Oefner P, Bogdahn U, Wischhusen J, Spang R, Storch A, Beier CP. Transcriptional profiles of CD133+ and CD133- glioblastomaderived cancer stem cells indicate different cells of origin. Cancer Res 2010; 70:2030-40
  146. Schwarz SC, Schwarz J. Translation of stem cell therapy for neurological diseases. Transl Res 2010; 156:155-60
  147. Maisel M, Habisch HJ, Royer L, Herr A, Milosevic J, Hermann A, Liebau S, Brenner R, Schwarz J, Schroeder M, Storch A. Genome-wide expression profiling and functional network analysis upon neuroectodermal conversion of human mesenchymal stem cells suggest HIF-1 and miR-124a as important regulators. Exp Cell Res 2010: 316:2760-78
  148. Wolz M, Löhle M, Strecker K, Schwanebeck U, Schneider C, Reichmann H, Grählert X, Schwarz J, Storch A. Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized double-blind, placebo-controlled trial. J Neural Transm 2010; 117:1279-86
  149. Schwarz J. Nuclear medicine imaging in patients with Parkinson’s syndrome: an update. Nervenarzt 2010; 81:1160-67
  150. Strecker K, Wegner F, Hesse S, Becker GA, Patt M, Meyer PM, Lobsien D, Schwarz J, Sabri O. Preserved serotonin transporter binding in de novo Parkinson’s disease: negative correlation with the dopamine transporter. J Neurol 2011: 258:19-26
  151. Skardelly M, Gaber K, Burdack S, Scheidt F, Hilbig H, Boltze J, Förschler A, Schwarz J, Schwarz S, Meixensberger J, Schuhmann MU, Long term benefit of human fetal progenitor cell transplantation in a clinically adapted model after traumatic brain injury. J Neurotrauma 2011; 28:253-62
  152. Skardelly M, Gaber K, Schwarz J, Milosevic J. Neuroprotectgive effects of beta-catenine stabilization in an oxygen- and glucose-deprived human neural progenitor cell culture system. Int J Dev Neurosci 2011; 29:543-7
  153. Isaias IU, Marotta G, Pezzoli G, Sabri O, Schwarz J, Crenna P, Classen J, Cavallari P. Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. BMC Neurol. 2011; 11:88
  154. Loewenbrück K, Fuchs B, Hermann A, Brandt M, Werner A, Schwarz SC, Schöler HR, Schwarz J, Schiller J, Storch A. Proton MR spectroscopy of neural stem cells: Does the peak at 1.28 ppm function as a biomarker for cell type or state? Rejuvenation Res 2011; 14:371-81
  155. Braun M, Winkler D, Wehner M, Busch T, Schwarz J. Deep brain stimulation and general anesthesia. Basal Ganglia 2011; 1:79-82 
  156. Wegner F, Kraft R, Busse K, Härtig W, Leffler A, Dengler R, Schwarz J. Differentiated human midbrain-derived neural progenitor cells express excitatory strychnine-sensitive glycine receptors containing α2β subunits. PLoS One 2012; 7:e36946
  157. Synofzik M, Soehn AS, Gburek-Augustat J, Schicks J, Karle KN, Schüle R, Haack TB, Schöning M, Biskup S, Rudnik-Schöneborn S, Senderek J, Hoffmann KT, MacLeod P, Schwarz J, Bender B, Krüger S, Kreuz F, Bauer P, Schöls L. Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum. Orphanet J Rare Dis 2013;8:41
  158. Garrido-Vásquez P, Pell MD, Paulmann S, Strecker K, Schwarz J, Kotz SA. An ERP study of vocal emotion processing in asymmetric Parkinson's disease. Soc Cogn Affect Neurosci 2013; 8:918-27
  159. Hermann A, Loewenbrück KF, Boldt Ä, Fiedler C, Maisel M, Kalucka J, Schwarz J, Breier G, Storch A. Lack of vascular endothelial growth factor receptor-2/Flk1 signaling does not affect substantia nigra development. Neurosci Lett. 2013; 553:142-7
  160. Winkler D, Hammer N, Oehlwein C, Schwarz J, Strecker K, Fritzsch D, Meixensberger J. Implementing conventional Zamorano Dujovny frames versus individually manufactured microTargeting platforms--a comparative study on deep brain stimulation in Parkinson patients. Stereotact Funct Neurosurg 2013; 91:392-8
  161. Lojewski X, Hermann A, Wegner F, Araúzo-Bravo MJ, Hallmeyer-Elgner S, Kirsch M, Schwarz J, Schöler HR, Storch A. Human adult white matter progenitor cells are multipotent neuroprogenitors similar to adult hippocampal progenitors. Stem Cells Transl Med 2014; 3:458-69
  162. Busse K, Strotmann R, Strecker K, Wegner F, Devanathan V, Gohla A, Schöneberg T, Schwarz J. Adaptive gene regulation in the Striatum of RGS9-deficient mice. PLoS ONE 2014;9(3):e92605
  163. Eggert K, Öhlwein C, Kassubek J, Wolz M, Kupsch A, Ceballos-Baumann A, Ehret R, Polzer U, Klostermann F, Schwarz J, Fuchs G, Jost W, Albert A, Haag A, Hermsen A, Lohmüller K, Kuhn K, Wangemann M, Oertel WH. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol 2014; 37(4):116-22
  164. Matzke C, Lindner D, Schwarz J, Classen J, Hammer N, Weise D, Rumpf JJ, Fritzsch D, Meixensberger J, Winkler D. A comparison of two surgical approaches in functional neurosurgery: individualized versus conventional stereotactic frames. Comput Aided Surg. 2015; 20:34-40
  165. Lojewski X, Srimasorn S, Rauh J, Francke S, Wobus M, Taylor V, Araúzo-Bravo MJ, Hallmeyer-Elgner S, Kirsch M, Schwarz S, Schwarz J, Storch A, Hermann A. Perivascular mesenchymal Stem Cells from the adult Human brain harbor no Instrinsic neuroectodermal but high mesodermal differentiation potential. Stem Cells Transl Med. 2015; 4:1223-33
  166. Weise D, Hammer N, Rumpf JJ, Meixensberger J, Schwarz J, Winkler D. Unilateral multi-target deep brain stimulation in hemidystonia and hemichoreoathetosis following ischemic thalamic stroke. Basal Ganglia 2016; 6:153-156
  167. Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Mov Disord 2016; 31:1049-54
  168. Jochim A, Gempt J, Deschauer M, Schwarz J, Kirschke JS, Haslinger B. Status epilepticus after subthalamic deep brain stimulation surgery in a patient with Parkinson´s disease. World Neurosurg 2016: S1878-8750(16)30735-5
  169. Levin J, Maaß S, Schuberth M, Respondek G, Paul F, Mansmann U, Oertel WH, Lorenzl S, Krismer F, Seppi K, Poewe W, Wenning G; PROMESA study group, Giese A, Bötzel K, Höglinger G. The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. J Neural Transm 2016; 123:439-45
  170. Moon J, Schwarz SC, Lee HS, Kang JM, Lee YE, Kim B, Sung MY, Höglinger G, Wegner F, Kim JS, Chung HM, Chang SW, Cha KY, Kim KS, Schwarz J. Preclinical Analysis of Fetal Human Mesencephalic Neural Progenitor Cell Lines: Characterization and Safety In Vitro and In Vivo. Stem Cell Transl Med 2017; 6:576-588
  171. Alkemade A, de Hollander G, Keuken MC, Schäfer A, Ott DVM, Schwarz J, Weise D, Kotz SA, Forstmann BU. Comparison of T2*-weighted and QSM contrasts in Parkinson's disease to visualize the STN with MRI. PLoS One. 2017;12:e0176130
  172. Weber A, Schwarz SC, Tost J, Trümbach D, Winter P, Busato F, Tacik P, Windhorst AC, Fagny M, Arzberger T, McLean C, van Swieten JC, Schwarz J, Vogt Weisenhorn D, Wurst W, Adhikary T, Dickson DW, Höglinger GU, Müller U. Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1. Nat Commun. 2018; 9:2929
  173. Kim HW, Lee HS, Kang JM, Bae SH, Kim C, Lee SH, Schwarz J, Kim GJ, Kim JS, Cha DH, Kim J, Chang SW, Lee TH, Moon J. Dual Effects of Human Placenta-Derived Neural Cells on Neuroprotection and the Inhibition of Neuroinflammation in a Rodent Model of Parkinson's Disease. Cell Transplant. 2018; 27:814-830
  174. Rozanski V, Laux G, Schwarz J. The Dopamine Receptor Antagonism of Opipramol: Relevance to Parkinsonism? Clin Neuropharmacol. 2019; 42:77-79
  175. Jost WH, Lingor P, Tönges L, Schwarz J, Buhmann C, Kassubek J, Schrag A. Dyskinesia in multiple system atrophy and progressive supranuclear palsy. J Neural Transm (Vienna). 2019;126:925-932
  176. Levin J, Maaß S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, Südmeyer M, Eggert K, Mollenhauer B, Lipp A, Löhle M, Classen J, Münchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, Bötzel K, Ertl-Wagner B, Huppertz HJ, Ricard I, Höglinger GU, PROMESA Study Group. Lancet Neurol 2019; 18:724-735
  177. Reichmann H, Lees A, Rocha JF, Magalhães D, Soares-da-Silva P; OPTIPARK investigators. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener. 2020; 4:9
  178. Fauser M, Pan-Montojo F, Richter C, Kahle PJ, Schwarz SC, Schwarz J, Storch A, Hermann A. Chronic-Progressive Dopaminergic Deficiency Does Not Induce Midbrain Neurogenesis. Cells 2021; 10:775
  179. Kurz A, Kumar R, Northoff BH, Wenk C, Schirra J, Donakonda S, Höglinger GU, Schwarz J, Rozanski V, Hübner R, Bötzel K, Holdt LM, Koeglsperger T. Differential expression of gut miRNAs in idiopathic Parkinson's disease. Pakinsonism Relat Disord 2021; 88:46-50
  180. Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. Parkinsonism Relat Disord. 2022; 96:65-73
  181. Kim J, Inbo H, Kim HS, Kim W, Jang SJ, Min K, Kim SH, Bae SH, Jeong YH, Kim B, Kim C, Schwarz SC, Schwarz J, Cho KG, Chung SS, Moon J. First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells. Mov Disord 2023; 38: 589-603
  182. Weiss D, Ebersbach G, Möller JC, Schwarz J, Arlt C, Fritz B, Sensken SC, Eggert K. Do we start too late? Insights from the real-world non-interventional BALANCE study on the present use of levodopa/carbidopa intestinal gel in advanced Parkinson's disease in Germany and Switzerland. Parkinsonim Relat Didsord 2022; 103:85-91
  183. Hauser RA, Espay AJ, Ellenbogen AL, Fernandez HH, Isaacson SH, LeWitt PA, Ondo WG, Pahwa R, Schwarz J, Stocchi F, Zeitlin L, Banisadr G, Fisher S, Visser H, D'Souza R. IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial. JAMA Neurol 2023; 80:1062-69
  184. Greten S, Wegner F, Jensen I, Krey L, Rogozinski S, Fehring M, Heine J, Doll-Lee J, Pötter-Nerger M, Zeitzschel M, Hagena K, Pedrosa DJ, Eggers C, Bürk K, Trenkwalder C, Claus I, Warnecke T, Süß P, Winkler J, Gruber D, Gandor F, Berg D, Paschen S, Classen J, Pinkhardt EH, Kassubek J, Jost WH, Tönges L, Kühn AA, Schwarz J, Peters O, Dashti E, Priller J, Spruth EJ, Krause P, Spottke A, Schneider A, Beyle A, Kimmich O, Donix M, Haussmann R, Brandt M, Dinter E, Wiltfang J, Schott BH, Zerr I, Bähr M, Buerger K, Janowitz D, Perneczky R, Rauchmann BS, Weidinger E, Levin J, Katzdobler S, Düzel E, Glanz W, Teipel S, Kilimann I, Prudlo J, Gasser T, Brockmann K, Hoffmann DC, Klockgether T, Krause O, Heck J, Höglinger GU, Klietz M. The comorbidity and co-medication profile of patients with progressive supranuclear palsy. J Neurol 2024; 271:782-793
  185. Pürner D, Hormozi M, Weiß D, Barbe MT, Jergas H, Prell T, Gülke E, Pötter-Nerger M, Falkenburger B, Klingelhöfer L, Gutsmiedl PK, Haslinger B, Jochim AM, Wolff A, Schröter N, Rijntjes M, van Riesen C, Scheller U, Wolz M, Amouzandeh A, Ebersbach G, Gruber D, Kohl Z, Maetzler W, Paschen S, Pérez-González P, Rozanski V, Schwarz J, Südmeyer M, Torka E, Wesbuer S, Bornmann S, Flöel A, Ip CW, Krause P, Kühn AA, Csoti I, Herting B, van de Loo S, Basheer AA, Liszka R, Jost WH, Koschel J, Haller B, Lingor P. Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease. Neurology 2023; 101:e2078-93
  186. Jensen I, Stiel S, Bebermeier S, Schrag A, Greten S, Doll-Lee J, Wegner F, Ye L, Heine J, Krey L, Höllerhage M, Süß P, Winkler J, Berg D, Paschen S, Tönges L, Gruber D, Gandor F, Jost WH, Kühn AA, Claus I, Warnecke T, Pedrosa DJ, Eggers C, Trenkwalder C, Classen J, Schwarz J, Pötter-Nerger M, Kassubek J, Schnitzler A, Höglinger GU, Klietz M. A Short Progressive Supranuclear Palsy Quality of Life Scale. Mov Disord. 2024; 39:1602-1609
  187. Kassubek J, Jost WH, Schwarz J. Sublingual apomorphine in the treatment of Parkinson's disease. J Neural Transm. 2024; 131:1209-1216
  188. Kassubek J, Factor SA, Balaguer E, Schwarz J, Chaudhuri KR, Isaacson SH, Wu S, Denecke Muhr C, Kulisevsky J. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study. J Neurol. 2024; 271:3554-3570

Übersichtsarbeiten

  1. Tatsch K, Schwarz J, Kirsch CM. ZNS-SPECT: Rezeptorszintigraphie mit 123J-IBZM und 123J-Iomazenil. Der Nuklearmediziner 1993; 16:143-150

  2. Oertel WH, Schwarz J, Tatsch K, Arnold G, Gasser T, Kirsch CM. IBZM-SPECT as predictor for dopaminergic responsiveness of patients with de novo Parkinsonian syndrome. Advances of Neurology 1993; 60:519-524

  3. Schwarz J. Morbus Parkinson - Diagnostik und Verlauf. Quintessenz Medizin 1993; 3:219-227
  4. Bandmann O, Schwarz J. Morbus Parkinson - Therapie. Quintessenz Medizin 1993; 3:229-237 

  5. Vogl Th J, Steiner S, Hammerstingl R, Schwarz J, Kraft E, Weinzierl M, Felix R. MRT der Leber bei Morbus Wilson. Fortschr Röntgenstr 1994; 160:40-45

  6. Oertel WH, Trenkwalder C, Gasser T, Schwarz J, Bucher SF, Eichhorn T, Pogarell O, Künig G, Arnold G, Bandmann O, Dodel RC. Epidemiological, genetic, pharmacological, kinesiological, nuclear medical (IBZM-SPECT), standard and functional MRI studies on Parkinson's disease and related disorders and economic evaluation of Parkinson's disease therapy - clinical projects in the BMFT-research program Munich: "Parkinson's disease and other basal ganglia disorders". J Neural Transm (PD section) 1995; 46 Suppl:325-337

  7. Schwarz J. Reduktion der Levodopa-Dosis bei Morbus Parkinson. Extracta Geriatrica 1996; 5:24-25

  8. Schwarz J, Trenkwalder C. Restless Legs Syndrom: Therapie mit L-Dopa bzw. L-Dopa-Retardformen. Aktuelle Neurologie 1996; 23:26-29

  9. Schwarz J. Tremordominanter Morbus Parkinson: Therapie mit Dopamin-Agonisten. Psycho 1997; 23:446-449

  10. Schwarz J. The value of single photon emission computed tomography in the diagnosis of neurological disorders. Nervenheilkunde 1999; 18: 71-74

  11. Schwarz J. Morbus Parkinson – Pathophysiologische Mechanismen und Therapiestrategien. Psycho 2002; 28:466-471

  12. Storch A, Schwarz J. Neural stem cells and neurodegeneration. Curr Opin Invest Drugs 2002, 3:774-781

  13. Schwarz J, Reichmann H. Parkinson’s disease and neuroprotection: Dream or reality. Akt Neurol 2003; 30:51-58

  14. Schwarz J. Ratonale for dopamine agonist use as monotherapy in Parkinson’s disease. Curr Opin Neurol 2003; 16 Suppl. 1:S27-S33

  15. Müller T, Hefter H, Hueber R, Jost, WH, Leenders KL, Odin P, Schwarz J. Is levodopa toxic? J Neurol 2004 Suppl 6;

Deutsche Gesellschaft für Neurologie
Deutsche Parkinson Gesellschaft
Deutsche Gesellschaft für Klinische Neurophysiologie und Funktionelle Bildgebung

Klinische Forschung
Experimentelle Forschung
Gutachter für wissenschaftliche Zeitschriften
Gutachter für nationale und internationale Förderinstitutionen
Berater für Unternehmen der pharmazeutischen Industrie

Dr. B. Wieder
Dr. med. Bettina Wieder
Leitende Oberärztin